Header Logo

JAFFER A AJANI

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525. PMID: 38297981; PMCID: PMC10994248.
      Citations:    Fields:    
    2. Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel). 2024 Mar 31; 16(7). PMID: 38611056.
      Citations:    
    3. Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers JE, Rosa Vicentini E, Pool Pizzi M, Fan Y, Zou G, Li JJ, Blum Murphy M, Gan Q, Waters RE, Wang L, Ajani JA. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel). 2024 Mar 27; 16(7). PMID: 38610978.
      Citations:    
    4. Strickland MR, Lander EM, Gibson MK, Ilson DH, Ajani JA, Klempner SJ. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management. J Natl Compr Canc Netw. 2024 Mar 19; 1-8. PMID: 38503041.
      Citations:    Fields:    
    5. Zou G, Huang Y, Zhang S, Ko KP, Kim B, Zhang J, Venkatesan V, Pizzi MP, Fan Y, Jun S, Niu N, Wang H, Song S, Ajani JA, Park JI. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. J Exp Med. 2024 Apr 01; 221(4). PMID: 38411616; PMCID: PMC10899090.
      Citations:    Fields:    Translation:HumansAnimals
    6. Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Feb 21; JCO2301601. PMID: 38382001.
      Citations:    Fields:    
    7. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 Feb 15. PMID: 38358339.
      Citations:    Fields:    
    8. Rogers JE, Ajani J. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma. Curr Oncol. 2024 Feb 01; 31(2):769-777. PMID: 38392051; PMCID: PMC10888045.
      Citations:    Fields:    Translation:Humans
    9. Badgwell B, Estrella J, Roy-Chowdhuri S, Ikoma N, Blum Murphy M, Ajani J, Mansfield P. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825. PMID: 38286882.
      Citations:    Fields:    
    10. Yonemura A, Semba T, Zhang J, Fan Y, Yasuda-Yoshihara N, Wang H, Uchihara T, Yasuda T, Nishimura A, Fu L, Hu X, Wei F, Kitamura F, Akiyama T, Yamashita K, Eto K, Iwagami S, Iwatsuki M, Miyamoto Y, Matsusaki K, Yamasaki J, Nagano O, Saya H, Song S, Tan P, Baba H, Ajani JA, Ishimoto T. Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. Cell Rep. 2024 01 23; 43(1):113613. PMID: 38232734.
      Citations:    Fields:    Translation:HumansCells
    11. Kim SB, Van Cutsem E, Ajani J, Shen L, Barnes G, Ding N, Tao A, Xia T, Zhan L, Kato K, Ajani J, Barnes G, Tao A, Xia T, Zhan L. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients. Curr Med Res Opin. 2024 Jan; 40(1):69-75. PMID: 37846080.
      Citations:    Fields:    Translation:Humans
    12. Ajani J, El Hajbi F, Cunningham D, Alsina M, Thuss-Patience P, Scagliotti GV, Van den Eynde M, Kim SB, Kato K, Shen L, Li L, Ding N, Shi J, Barnes G, Van Cutsem E. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 2024 Jan; 9(1):102202. PMID: 38118368; PMCID: PMC10837773.
      Citations:    Translation:HumansCTClinical Trials
    13. Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pool Pizzi M, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA, Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pizzi MP, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. 2023 11 15; 83(22):3726-3738. PMID: 37738407; PMCID: PMC10843008.
      Citations:    Fields:    Translation:AnimalsCells
    14. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398. PMID: 37279095; PMCID: PMC10618648.
      Citations:    Fields:    
    15. Rogers JE, Yamashita K, Sewastjanow-Silva M, Trail A, Waters RE, Ajani J. Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target. Cancers (Basel). 2023 Oct 27; 15(21). PMID: 37958354; PMCID: PMC10650285.
      Citations:    
    16. Hirata Y, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum Murphy M, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel). 2023 Oct 25; 15(21). PMID: 37958312; PMCID: PMC10650394.
      Citations:    
    17. Zou G, Huang Y, Zhang S, Ko KP, Kim B, Zhang J, Venkatesan V, Pizzi MP, Fan Y, Jun S, Niu N, Wang H, Song S, Ajani JA, Park JI. CDH1 loss promotes diffuse-type gastric cancer tumorigenesis via epigenetic reprogramming and immune evasion. bioRxiv. 2023 Oct 11. PMID: 36993615; PMCID: PMC10055394.
      Citations:    
    18. Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10; 41(35):5388-5399. PMID: 37713657; PMCID: PMC10713185.
      Citations:    Fields:    Translation:Humans
    19. Jeong YS, Eun YG, Lee SH, Kang SH, Yim SY, Kim EH, Noh JK, Sohn BH, Woo SR, Kong M, Nam DH, Jang HJ, Lee HS, Song S, Oh SC, Lee J, Ajani JA, Lee JS. Clinically conserved genomic subtypes of gastric adenocarcinoma. Mol Cancer. 2023 09 06; 22(1):147. PMID: 37674200; PMCID: PMC10481468.
      Citations: 1     Fields:    Translation:HumansCells
    20. Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers (Basel). 2023 Aug 31; 15(17). PMID: 37686627; PMCID: PMC10486659.
      Citations: 1     
    21. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984. PMID: 37339271; PMCID: PMC10751575.
      Citations:    Fields:    
    22. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141. PMID: 37524953; PMCID: PMC10427418.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    23. Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, Wang L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. 2023 08 14; 41(8):1407-1426.e9. PMID: 37419119; PMCID: PMC10528152.
      Citations: 2     Fields:    Translation:HumansCells
    24. Trail A, Rogers J, Ajani J. Can You Establish the Cause of This Patient's Shortness of Breath? J Adv Pract Oncol. 2023 Jul; 14(5):440-443. PMID: 37576362; PMCID: PMC10414527.
      Citations:    
    25. Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 07; 24(7):744-756. PMID: 37329891.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    26. Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023 06 02; 28(6):553-e472. PMID: 36940261; PMCID: PMC10243783.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    27. Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. 2023 07; 20(7):453-469. PMID: 37264184.
      Citations: 2     Fields:    Translation:HumansCells
    28. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562. PMID: 37248301.
      Citations: 5     Fields:    Translation:HumansCells
    29. Zhao S, Wang R, Song S, Hao D, Han G, Song X, Zhang J, Pizzi MP, Shanbhag N, Futreal A, Badgwell B, Harada K, Calin G, Vykoukal J, Yu CY, Katayama H, Hanash SM, Wang L, Ajani JA. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases. iScience. 2023 Jun 16; 26(6):106913. PMID: 37305699; PMCID: PMC10251128.
      Citations:    
    30. Rogers JE, Yamashita K, Sewastjanow-Silva M, Rosa Vicentini E, Waters R, Ajani JA. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. Expert Rev Anticancer Ther. 2023 06; 23(6):565-571. PMID: 37122102.
      Citations:    Fields:    Translation:Humans
    31. Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules. 2023 05 06; 13(5). PMID: 37238666; PMCID: PMC10216443.
      Citations:    Fields:    Translation:Humans
    32. Hirata Y, Agnes A, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945. PMID: 37106276.
      Citations:    Fields:    Translation:Humans
    33. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326. PMID: 37080372.
      Citations:    Fields:    
    34. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668. PMID: 37068504.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    35. Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 04; 21(4):393-422. PMID: 37015332.
      Citations: 7     Fields:    Translation:Humans
    36. Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P, Singapore Gastric Cancer Consortium. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023 09; 72(9):1651-1663. PMID: 36918265.
      Citations:    Fields:    Translation:Humans
    37. Rogers JE, Ajani JA. Recent advances in the management of gastric adenocarcinoma patients. Fac Rev. 2023; 12:2. PMID: 36873983; PMCID: PMC9975945.
      Citations:    
    38. Jin J, Huo L, Fan Y, Wang R, Scott AW, Pizzi MP, Yao X, Shao S, Ma L, Da Silva MS, Yamashita K, Yoshimura K, Zhang B, Wu J, Wang L, Song S, Ajani JA. A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model. Front Oncol. 2023; 13:1062424. PMID: 36865791; PMCID: PMC9972586.
      Citations: 1     
    39. Yoon HH, Shi Q, Ajani JA. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply. JAMA Oncol. 2023 02 01; 9(2):280-281. PMID: 36547945.
      Citations:    Fields:    Translation:Humans
    40. Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. 2022 Dec 02; 10(12):1441-1461. PMID: 36129967.
      Citations:    
    41. Kharofa JR, Yothers G, Kachnic LA, Ajani J, Meyer JE, Augspurger ME, Okawara GS, Garg MK, Schefter TE, Swanson TA, Doncals DE, Kim H, Zaki BI, Narayan S, Lee RJ, Mamon HJ, Schwartz MA, Moughan J, Crane CH. Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. Am J Clin Oncol. 2022 12 01; 45(12):534-536. PMID: 36413683; PMCID: PMC9912479.
      Citations:    Fields:    Translation:Humans
    42. Vassilakopoulou M, Chen HC, Wang X, Harada K, Iwatsuki M, Das P, Blum Murphy M, Matamoros A, Sagebiel T, Devine C, Thomas I, Sanders EM, Shanbhag N, Rogers JE, Lee JH, Weston B, Bhutani MS, Hofstetter W, Nguyen QN, Badgwell BD, Ajani JA. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158. PMID: 36412619.
      Citations:    Fields:    Translation:Humans
    43. Rogers JE, Ajani JA. Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go? Expert Opin Pharmacother. 2022 Dec; 23(17):1893-1902. PMID: 36286544.
      Citations:    Fields:    Translation:Humans
    44. Sewastjanow-Silva M, Yamashita K, Rosa Vicentini E, Hirschmann M, Pool Pizzi M, Trail AM, Waters RE, Rogers JE, Ajani JA. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives. Expert Rev Anticancer Ther. 2022 Nov; 22(11):1177-1181. PMID: 36266061.
      Citations:    Fields:    Translation:Humans
    45. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78. PMID: 36302890; PMCID: PMC9612600.
      Citations: 1     
    46. Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022 10 01; 8(10):1456-1465. PMID: 36006624; PMCID: PMC9412834.
      Citations:    
    47. Rogers JE, Yamashita K, Sewastjanow Silva M, Ajani JA. Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. Cancers (Basel). 2022 Sep 30; 14(19). PMID: 36230726; PMCID: PMC9563283.
      Citations:    
    48. Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep; 18(29):3255-3266. PMID: 36000541.
      Citations:    
    49. Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2023 04; 72(4):624-637. PMID: 36002248.
      Citations:    
    50. Li Y, Fan Y, Xu J, Huo L, Scott AW, Jin J, Yang B, Shao S, Ma L, Wang Y, Yao X, Pool Pizzi M, Sewastjanow Da Silva M, Zhang G, Zhuo L, Cho EJ, Dalby KN, Shanbhag ND, Wang Z, Li W, Song S, Ajani JA. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma. J Exp Clin Cancer Res. 2022 Aug 23; 41(1):257. PMID: 35996148; PMCID: PMC9396876.
      Citations:    
    51. Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol. 2022 08; 6:e2200049. PMID: 35952321.
      Citations:    
    52. Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 2022 08; 7(4):100517. PMID: 35785595; PMCID: PMC9434166.
      Citations:    
    53. Kumar S, Bahdi F, Emelogu IK, Yu AC, Coronel M, Ge PS, Coronel E, Ajani JA, Weston B, Lynch P, Ross WA, Lee JH. How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia. Dis Esophagus. 2022 Jun 15; 35(6). PMID: 34937091.
      Citations:    Fields:    Translation:Humans
    54. Rogers JE, Ajani JA. Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma. Ann Palliat Med. 2022 06; 11(6):2180-2183. PMID: 35695051.
      Citations:    Fields:    Translation:Humans
    55. Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol. 2022 Jul; 18(21):2623-2634. PMID: 35616013.
      Citations:    Fields:    Translation:Humans
    56. Ajani JA, Leung L, Singh P, Kurt M, Kim I, Pourrahmat MM, Kanters S. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. Eur J Cancer. 2022 07; 170:119-130. PMID: 35605522.
      Citations:    Fields:    Translation:Humans
    57. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E, RATIONALE-302 Investigators, Borg C. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 09 10; 40(26):3065-3076. PMID: 35442766; PMCID: PMC9462531.
      Citations: 4     Fields:    
    58. Shitara K, Ajani JA, Moehler M, Shen L, Yamaguchi K, Wyrwicz L, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY, Garrido M, Gallardo C, Skoczylas T, Bruges R, Zander T, de Azevedo S. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 03; 603(7903):942-948. PMID: 35322232; PMCID: PMC8967713.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    59. van der Wilk BJ, Eyck BM, Hofstetter WL, Ajani JA, Piessen G, Castoro C, Alfieri R, Kim JH, Kim SB, Furlong H, Walsh TN, Nieboer D, Wijnhoven BPL, Lagarde SM, Lanschot JJBV. Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis. Ann Surg. 2022 03 01; 275(3):467-476. PMID: 34191461.
      Citations:    Fields:    Translation:Humans
    60. Harada K, Yamashita K, Iwatsuki M, Baba H, Ajani JA. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis. Expert Rev Clin Pharmacol. 2022 Jan; 15(1):43-49. PMID: 35184625.
      Citations:    Fields:    Translation:Humans
    61. Shah MA, Udrea AA, Bondarenko I, Mansoor W, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C, Pikiel J, Kalofonos HP, Wojcik E, Buchler T, Swinson D, Cicin I, Joseph M, Vynnychenko I, Luft AV, Enzinger PC, Salek T, Papandreou C, Maiello E, Wei R, Ferry D, Gao L, Oliveira JM, Ajani JA, S?nchez RG, ?zg?roglu M, Tournigand C. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers (Basel). 2022 Feb 24; 14(5). PMID: 35267477; PMCID: PMC8909008.
      Citations:    
    62. Fu L, Yonemura A, Yasuda-Yoshihara N, Umemoto T, Zhang J, Yasuda T, Uchihara T, Akiyama T, Kitamura F, Yamashita K, Okamoto Y, Bu L, Wei F, Hu X, Liu Y, Ajani JA, Tan P, Baba H, Ishimoto T. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric Cancer. 2022 05; 25(3):542-557. PMID: 35166958.
      Citations:    Fields:    Translation:HumansAnimals
    63. Rogers JE, Sewastjanow-Silva M, Waters RE, Ajani JA. Esophageal cancer: emerging therapeutics. Expert Opin Ther Targets. 2022 02; 26(2):107-117. PMID: 35119973.
      Citations:    Fields:    Translation:Humans
    64. CheckMate 648 Trial Investigators, Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 02 03; 386(5):449-462. PMID: 35108470.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    65. Rogers JE, Trail A, Ajani JA. Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms? J Natl Compr Canc Netw. 2022 02; 20(2):100-101. PMID: 35130497.
      Citations:    Fields:    Translation:Humans
    66. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 02; 20(2):167-192. PMID: 35130500.
      Citations: 16     Fields:    Translation:Humans
    67. Rogers JE, Sewastjanow D Silva M, Waters RE, Ajani JA. Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opin Pharmacother. 2022 Apr; 23(5):611-621. PMID: 35098851.
      Citations:    Fields:    Translation:Humans
    68. De Silva Sewastjanow M, Rogers JE, Hofstetter WL, Ajani JA. Esophageal cancer: Is the CROSS strategy ready for history books? J Thorac Cardiovasc Surg. 2023 03; 165(3):901-905. PMID: 35184889.
      Citations:    Fields:    
    69. Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol. 2022 Jan 15; 14(1):181-202. PMID: 35116110; PMCID: PMC8790425.
      Citations:    
    70. Fan Y, Ajani JA, Song S. Proteomic profiling of key signatures from gastric lesions to early gastric cancer. EBioMedicine. 2021 Dec; 74:103744. PMID: 34902787; PMCID: PMC8671089.
      Citations:    Fields:    Translation:Humans
    71. Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021; 16(12):e0260857. PMID: 34882728; PMCID: PMC8659695.
      Citations: 2     Fields:    Translation:HumansCells
    72. Zhou N, Hofstetter WL, Esophageal Squamous Cell Carcinoma Working Group, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040. PMID: 34883083.
      Citations:    Fields:    
    73. Rogers JE, Wang X, Trail A, Ajani JA. Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? Oncology. 2022; 100(3):182-187. PMID: 34969028.
      Citations:    Fields:    Translation:Humans
    74. VanderWalde N, Moughan J, Lichtman SM, Jagsi R, Ballo M, VanderWalde A, Mohiuddin M, Meropol NJ, Kachnic L, Berger A, Ajani J, Anne R, Hopkins JL, Arora A, Meyer J, Ellsworth SG, Lee RJ, Green N, Crane CH. The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. J Geriatr Oncol. 2022 04; 13(3):294-301. PMID: 34756496; PMCID: PMC8967782.
      Citations:    Fields:    Translation:Humans
    75. Zhou N, Mitchell KG, Corsini EM, Truong VTT, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215. PMID: 34095952.
      Citations:    Fields:    Translation:Humans
    76. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw. 2021 Oct 22; 1-12. PMID: 34678759.
      Citations: 1     Fields:    
    77. Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548. PMID: 34132693; PMCID: PMC8988446.
      Citations: 1     Fields:    Translation:Humans
    78. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606. PMID: 34556668; PMCID: PMC8460828.
      Citations: 13     Fields:    Translation:HumansCells
    79. Cameron RB, Ajani JA, Wu AJ. Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm. J Thorac Cardiovasc Surg. 2022 08; 164(2):433-437. PMID: 34663521.
      Citations:    Fields:    Translation:Humans
    80. Abdelhakeem A, Patnana M, Wang X, Rogers JE, Murphy MB, Sagebiel T, Ikoma N, Badgwell BD, Trail A, Estrella JS, Lu Y, Devine C, Ajani JA. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology. 2021; 99(10):659-664. PMID: 34352788.
      Citations:    Fields:    Translation:Humans
    81. Ajani JA. Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol. 2021; 6:49. PMID: 34423170; PMCID: PMC8343420.
      Citations:    
    82. Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med. 2021 Jul; 9(14):1189. PMID: 34430630; PMCID: PMC8350624.
      Citations: 3     
    83. Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res. 2021 Jun 23; 40(1):207. PMID: 34162421; PMCID: PMC8223395.
      Citations:    Fields:    Translation:HumansAnimalsCells
    84. Janjigian YY, Shitara K, Moehler M, Shen L, Wyrwicz L, Yamaguchi K, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA, Garrido M, Salman P, Skoczylas T, Bruges R, Zander T. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 07 03; 398(10294):27-40. PMID: 34102137; PMCID: PMC8436782.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    85. Shin MK, Kim J, Kim D, Lee SH, Shin JH, Jeong YS, Sohn BH, Kim J, Kim SR, Ajani JA, Lee JS, Cheong JH. Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clin Transl Med. 2021 06; 11(6):e421. PMID: 34185430; PMCID: PMC8181196.
      Citations:    Fields:    Translation:Humans
    86. Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed MM. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst. 2021 06 01; 113(6):665-679. PMID: 33351071; PMCID: PMC8600025.
      Citations: 1     Fields:    Translation:Humans
    87. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239. PMID: 34059344.
      Citations: 2     Fields:    Translation:Humans
    88. CheckMate 577 Investigators, Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Li?vre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203. PMID: 33789008.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    89. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757. PMID: 31188215.
      Citations: 1     Fields:    Translation:Humans
    90. Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. 2022 03; 71(3):467-478. PMID: 33785559; PMCID: PMC9724309.
      Citations: 1     Fields:    Translation:AnimalsCells
    91. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2021 Mar 25; 20(1):56. PMID: 33766033; PMCID: PMC7992986.
      Citations: 1     Fields:    
    92. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD, Ikoma N. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6638-6648. PMID: 33754224.
      Citations:    Fields:    Translation:Humans
    93. Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, Song SM, Han WD, Yu L, Wei MB, Pang XL, He F, Liu S, Zheng J, Ma Y, Lin CY, Lan P, Huang MJ, Zou YF, Yang ZL, Wang T, Lang JY, Orangio GR, Poylin V, Ajani JA, Wang WH, Wan XB. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist. 2021 05; 26(5):e780-e793. PMID: 33543577; PMCID: PMC8100558.
      Citations: 4     Fields:    Translation:Humans
    94. Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021 02 15; 19(1):19. PMID: 33588867; PMCID: PMC7885480.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    95. Shah MA, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA, Bodoky G. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 03 20; 39(9):990-1000. PMID: 33577358; PMCID: PMC8078292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    96. Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, Li CY, Estrella JS, Correa A, Pizzi MP, Ma L, Jin J, Liu B, Wang Y, Xiao L, Hofstetter WL, Lee JH, Weston B, Bhutani M, Shanbhag N, Johnson RL, Gan B, Wei S, Ajani JA. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021 12; 70(12):2238-2248. PMID: 33487592; PMCID: PMC9720890.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    97. Abdelhakeem AA, Wang X, Waters RE, Patnana M, Estrella JS, Blum Murphy M, Trail AM, Lu Y, Devine CE, Ikoma N, Das P, Badgwell BD, Rogers JE, Ajani JA. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel). 2021 Jan 23; 13(3). PMID: 33498613; PMCID: PMC7866002.
      Citations:    
    98. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670. PMID: 33414133; PMCID: PMC7956157.
      Citations: 7     Fields:    Translation:HumansCells
    99. Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922. PMID: 33400838; PMCID: PMC7906958.
      Citations: 1     Fields:    Translation:Humans
    100. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151. PMID: 33398161; PMCID: PMC8074162.
      Citations: 30     Fields:    Translation:HumansCells
    101. Cascinu S, Muro K, Van Cutsem E, Oh SC, Ananda S, Wainberg ZA, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A, Bodoky G, Folprecht G, Girotto G, Miron MLL. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist. 2021 03; 26(3):e414-e424. PMID: 33274542; PMCID: PMC7930430.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    102. Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065. PMID: 33334899; PMCID: PMC10643023.
      Citations: 11     Fields:    Translation:Humans
    103. Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ohmuraya M, Wang X, Ajani JA, Sawa T, Baba H. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021 03; 124(5):963-974. PMID: 33299132; PMCID: PMC7921654.
      Citations: 13     Fields:    Translation:HumansCells
    104. Rogers JE, Trail A, Ajani JA. Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone? Chin Clin Oncol. 2021 Jun; 10(3):32. PMID: 33222442.
      Citations:    Fields:    Translation:Humans
    105. Davis CH, Ikoma N, Mansfield PF, Das P, Minsky BD, Blum MA, Ajani JA, Bass BL, Badgwell BD. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc. 2021 12; 35(12):6577-6582. PMID: 33170336.
      Citations:    Fields:    Translation:Humans
    106. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020 11 02; 130(11):5951-5966. PMID: 33016929; PMCID: PMC7598069.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    107. Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res. 2020; 10(11):3947-3972. PMID: 33294279; PMCID: PMC7716160.
      Citations: 4     
    108. Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med. 2020 Oct 29; 9(11). PMID: 33138060; PMCID: PMC7692279.
      Citations: 2     
    109. Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, Eto K, Kurashige J, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Ajani JA, Baba H. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer. 2021 02; 124(3):595-603. PMID: 33100329; PMCID: PMC7851117.
      Citations: 3     Fields:    Translation:HumansCells
    110. Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel). 2020 Oct 15; 12(10). PMID: 33076512; PMCID: PMC7602573.
      Citations: 4     
    111. Yao X, Ajani JA, Song S. Molecular biology and immunology of gastric cancer peritoneal metastasis. Transl Gastroenterol Hepatol. 2020; 5:57. PMID: 33073052; PMCID: PMC7530317.
      Citations: 4     
    112. Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res. 2020; 9. PMID: 33042518; PMCID: PMC7531047.
      Citations: 7     Fields:    Translation:Humans
    113. Abdelhakeem A, Wang X, Rogers JE, Trail A, Zhao M, Blum-Murphy M, Estrella JS, Ajani JA. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888. PMID: 32998149; PMCID: PMC10604547.
      Citations:    Fields:    Translation:Humans
    114. Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer. 2020 Sep; 20(3):313-327. PMID: 33024587; PMCID: PMC7521984.
      Citations: 2     
    115. He F, Yu L, Ding Y, Li ZH, Wang J, Zheng J, Chen HY, Liu S, Pang XL, Ajani JA, Wan XB. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci. 2020 Nov; 111(11):4205-4217. PMID: 32860448; PMCID: PMC7648035.
      Citations: 2     Fields:    Translation:Humans
    116. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Esophageal Adenocarcinoma Working Group, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2. PMID: 33010880.
      Citations: 2     Fields:    Translation:Humans
    117. Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140. PMID: 32857997.
      Citations:    Fields:    Translation:Humans
    118. Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol. 2020 Dec; 122(7):1373-1382. PMID: 32810292; PMCID: PMC7722201.
      Citations: 1     Fields:    Translation:Humans
    119. Chen B, Dragomir MP, Fabris L, Bayraktar R, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, De Los Santos MC, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA, Knutsen E. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020 12; 159(6):2146-2162.e33. PMID: 32805281; PMCID: PMC7725986.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    120. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318. PMID: 32675544.
      Citations: 5     Fields:    Translation:HumansCells
    121. Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2020 Dec; 27(13):5047-5056. PMID: 32737700; PMCID: PMC7682939.
      Citations: 5     Fields:    Translation:Humans
    122. He F, Ju HQ, Ding Y, Jiang Z, Li Z, Huang B, Wang X, Zhao Y, Li Y, Qi B, Luo W, Zhang Z, Pei Q, Chen H, Liu S, Pang X, Zheng J, Wang J, Ajani JA, Wan XB. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. Br J Cancer. 2020 10; 123(8):1244-1252. PMID: 32724220; PMCID: PMC7553967.
      Citations: 3     Fields:    Translation:Humans
    123. Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol. 2021 Feb; 28(2):758-765. PMID: 32696305; PMCID: PMC7855908.
      Citations: 2     Fields:    Translation:Humans
    124. White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol. 2020 Dec; 27(13):4963-4969. PMID: 32648181; PMCID: PMC8601118.
      Citations: 2     Fields:    Translation:Humans
    125. Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, Hayashi H, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Yashiro M, Masuda M, Ajani JA, Tan P, Baba H, Ishimoto T. Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing ?1 Integrin, Enhancing Drug Resistance. Cancer Res. 2020 08 15; 80(16):3222-3235. PMID: 32605995.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    126. Rogers JE, Ajani JA. The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. Chin Clin Oncol. 2021 Jun; 10(3):30. PMID: 32576019.
      Citations:    Fields:    Translation:Humans
    127. Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA. Palliative care for advanced gastric cancer. Expert Rev Anticancer Ther. 2020 07; 20(7):575-580. PMID: 32543938; PMCID: PMC7415645.
      Citations: 3     Fields:    Translation:Humans
    128. Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2021 Jan; 28(1):258-264. PMID: 32556731.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    129. Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387. PMID: 32542556.
      Citations: 5     Fields:    Translation:Humans
    130. Yamashita K, Iwatsuki M, Ajani JA, Baba H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Ann Gastroenterol Surg. 2020 Jul; 4(4):369-378. PMID: 32724880; PMCID: PMC7382440.
      Citations: 2     
    131. Seriak D, Menshikova S, Vakhabova Y, Ajani JA, Ignatova E, Fedyanin M, Tryakin A, Pokataev I, Smirnova K, Tjulandin S. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020 11; 23(6):951-960. PMID: 32514646.
      Citations: 11     Fields:    Translation:HumansCells
    132. Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432. PMID: 32462681; PMCID: PMC7731155.
      Citations: 2     Fields:    Translation:Humans
    133. Mizrak Kaya D, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA, Nogueras Gonz?lez GM. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548. PMID: 32434189.
      Citations: 2     Fields:    Translation:Humans
    134. Harada K, Patnana M, Wang X, Iwatsuki M, Murphy MAB, Zhao M, Das P, Minsky BD, Weston B, Lee JH, Bhutani MS, Estrella JS, Shanbhag N, Ikoma N, Badgwell BD, Ajani JA. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today. 2020 Oct; 50(10):1223-1231. PMID: 32409870; PMCID: PMC9396945.
      Citations:    Fields:    Translation:HumansCells
    135. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773. PMID: 32377978; PMCID: PMC7575509.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    136. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020 09; 23(5):904-912. PMID: 32347396; PMCID: PMC7442686.
      Citations: 3     Fields:    Translation:Humans
    137. Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021 01; 70(1):55-66. PMID: 32345613.
      Citations: 14     Fields:    Translation:HumansAnimals
    138. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, Minsky BD, Hofstetter WL, Mansfield P, Badgwell BD, Ikoma N. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405. PMID: 32289300.
      Citations: 6     Fields:    Translation:Humans
    139. Song S, Li Y, Xu Y, Ma L, Pool Pizzi M, Jin J, Scott AW, Huo L, Wang Y, Lee JH, Bhutani MS, Weston B, Shanbhag ND, Johnson RL, Ajani JA. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020 06; 14(6):1410-1426. PMID: 32175692; PMCID: PMC7266288.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    140. Duleba M, Yamamoto Y, Neupane R, Rao W, Xie J, Qi Y, Liew AA, Niroula S, Zhang Y, Mahalingam R, Wang S, Goller K, Ajani JA, Vincent M, Ho KY, Hou JK, Hyams JS, Sylvester FA, Crum CP, McKeon F, Xian W. Cloning of ground-state intestinal stem cells from endoscopic biopsy samples. Nat Protoc. 2020 05; 15(5):1612-1627. PMID: 32238950.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    141. Lu Y, Wang L, Ajani JA. Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. Clin Nucl Med. 2020 Apr; 45(4):334-335. PMID: 31977493.
      Citations:    Fields:    Translation:Humans
    142. Schizas D, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Psyrri A, Karamouzis MV, Liakakos T, Zhao M, Ajani JA. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy. 2020 02; 12(3):203-218. PMID: 32208794.
      Citations: 9     Fields:    Translation:HumansCells
    143. Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3). PMID: 31313820.
      Citations: 3     Fields:    Translation:Humans
    144. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579. PMID: 32160096; PMCID: PMC7213588.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    145. Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294. PMID: 32097933.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    146. Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020 Feb 17; 18(1):39. PMID: 32066454; PMCID: PMC7026970.
      Citations: 5     Fields:    Translation:Humans
    147. Jin J, Xu Y, Huo L, Ma L, Scott AW, Pizzi MP, Li Y, Wang Y, Yao X, Song S, Ajani JA. An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. PLoS One. 2020; 15(2):e0228910. PMID: 32053639; PMCID: PMC7018052.
      Citations: 5     Fields:    Translation:HumansCells
    148. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. 2020 04; 69(4):748-763. PMID: 32034004.
      Citations: 69     Fields:    Translation:Humans
    149. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020 Feb; 99(9):e19295. PMID: 32118743; PMCID: PMC7478597.
      Citations: 1     Fields:    Translation:Humans
    150. Van Cutsem E, Muro K, Cunningham D, Sobrero A, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators, Bodoky G, Cascinu S. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 03; 127:150-157. PMID: 32014812.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    151. Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J, Badgwell B. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811. PMID: 31974712.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    152. Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020 02; 30(2):146-162. PMID: 31949285; PMCID: PMC7015061.
      Citations: 166     Fields:    Translation:HumansAnimalsCells
    153. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12). PMID: 31732509; PMCID: PMC6918774.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    154. Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, Xu Y, Estrella JS, Song Y, Liu B, Johnson RL, Ajani JA. PPARd Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res. 2020 03; 18(3):390-402. PMID: 31796534.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    155. Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376. PMID: 32529130; PMCID: PMC7276694.
      Citations: 3     
    156. Xu Y, Song S, Wang Z, Ajani JA. The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. Cell Commun Signal. 2019 11 27; 17(1):157. PMID: 31775795; PMCID: PMC6882007.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    157. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. 2020 05; 24(5):1018-1025. PMID: 31754987.
      Citations: 7     Fields:    Translation:Humans
    158. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604. PMID: 31529018; PMCID: PMC6749545.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    159. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3. PMID: 32923865; PMCID: PMC7446516.
      Citations: 4     Fields:    
    160. Ahmed O, Ajani JA, Lee JH. Endoscopic management of esophageal cancer. World J Gastrointest Oncol. 2019 Oct 15; 11(10):830-841. PMID: 31662822; PMCID: PMC6815921.
      Citations: 7     
    161. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec; 120(8):1350-1357. PMID: 31612494.
      Citations: 4     Fields:    Translation:Humans
    162. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019 10 10; 18(1):141. PMID: 31601234; PMCID: PMC6785865.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    163. Rivin Del Campo E, Matzinger O, Haustermans K, Glynne-Jones R, Winter KA, Konski AA, Ajani JA, Hannoun-Levi JM, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Peiffert D, Bosset JF, Puyraveau M, Maingon P. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019 11; 121:130-143. PMID: 31574418; PMCID: PMC6924923.
      Citations: 2     Fields:    Translation:Humans
    164. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol. 2020 Feb; 27(2):534-542. PMID: 31552618.
      Citations: 2     Fields:    Translation:Humans
    165. Wang L, Ajani JA. Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. Clin Cancer Res. 2019 12 01; 25(23):6887-6889. PMID: 31527165.
      Citations: 6     Fields:    Translation:HumansCells
    166. Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. 2019 Dec; 120(7):1137-1141. PMID: 31498442.
      Citations: 1     Fields:    Translation:Humans
    167. Rogers JE, Ajani JA. Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. J Clin Oncol. 2019 10 20; 37(30):2805-2806. PMID: 31465257.
      Citations: 2     Fields:    Translation:Humans
    168. Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020 01; 23(1):95-104. PMID: 31451991.
      Citations: 23     Fields:    Translation:HumansCells
    169. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610. PMID: 31350645.
      Citations: 8     Fields:    Translation:Humans
    170. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. 2019; 11:1758835919864850. PMID: 31384313; PMCID: PMC6659187.
      Citations: 6     
    171. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget. 2019 Jul 23; 10(45):4703-4718. PMID: 31384397; PMCID: PMC6659793.
      Citations: 4     Fields:    
    172. Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019 07; 121(3):278-280. PMID: 31285589; PMCID: PMC6738080.
      Citations: 4     Fields:    Translation:Humans
    173. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883. PMID: 31319389.
      Citations: 179     Fields:    Translation:Humans
    174. Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM. Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. Cancers (Basel). 2019 06 21; 11(6). PMID: 31234436; PMCID: PMC6627221.
      Citations:    
    175. Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31. PMID: 31171626; PMCID: PMC6943252.
      Citations: 29     Fields:    Translation:Humans
    176. Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G. The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019 08; 18(8):1439-1450. PMID: 31142662; PMCID: PMC8345820.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    177. Harada K, Zhao M, Baba H, Ajani JA. Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma. Dig Med Res. 2019 Apr; 2. PMID: 31179442; PMCID: PMC6553865.
      Citations:    
    178. Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258. PMID: 30893708.
      Citations: 4     Fields:    Translation:Humans
    179. Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019 11; 22(6):1100-1108. PMID: 30854619.
      Citations: 1     Fields:    Translation:HumansCells
    180. Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM, van den Boorn HG. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel). 2019 Feb 05; 11(2). PMID: 30764578; PMCID: PMC6406639.
      Citations: 8     
    181. Shah MA, Kang YK, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL, Thuss-Patience PC. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 07; 22(4):803-816. PMID: 30706247.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    182. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400. PMID: 30680477.
      Citations: 10     Fields:    Translation:Humans
    183. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019 Jan; 79(1):63-74. PMID: 30617958.
      Citations: 18     Fields:    Translation:Humans
    184. Harada K, Abdelhakeem AAF, Ajani JA. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nat Rev Clin Oncol. 2019 01; 16(1):9-10. PMID: 30291292.
      Citations: 2     Fields:    Translation:Humans
    185. Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019 02; 108:17-24. PMID: 30592991.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    186. Iwatsuki M, Harada K, Baba H, Ajani JA. Higher rate of colon polyp detection aided by an artificial intelligent software. Transl Gastroenterol Hepatol. 2018; 3:106. PMID: 30701213; PMCID: PMC6327163.
      Citations: 1     
    187. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019 04 01; 25(7):2264-2277. PMID: 30563933.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    188. Morlock R, Maeda H, Ajani J, Casamayor M. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018; 12:883. PMID: 30679950; PMCID: PMC6345079.
      Citations: 24     
    189. Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA. Cancer stem cells in esophageal cancer and response to therapy. Cancer. 2018 10 15; 124(20):3962-3964. PMID: 30368777; PMCID: PMC6234092.
      Citations: 4     Fields:    Translation:HumansCells
    190. Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2019 Jan; 3(1):43-49. PMID: 30697609; PMCID: PMC6345649.
      Citations: 7     
    191. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-? Superfamily. Cell Syst. 2018 10 24; 7(4):422-437.e7. PMID: 30268436; PMCID: PMC6370347.
      Citations: 63     Fields:    Translation:HumansCells
    192. Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 09 18; 8(1):14006. PMID: 30228315; PMCID: PMC6143616.
      Citations: 11     Fields:    Translation:Humans
    193. Ajani JA, Bhutani MS, Swisher SG. Oesophageal preservation in locally advanced oesophageal cancer. Lancet Oncol. 2018 09; 19(9):e430. PMID: 30191840.
      Citations: 1     Fields:    Translation:Humans
    194. Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018; 7. PMID: 30228868; PMCID: PMC6117861.
      Citations: 10     Fields:    Translation:Humans
    195. Harada K, Song S, Ajani JA. Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. Oncoscience. 2018 Jul; 5(7-8):214-215. PMID: 30234141; PMCID: PMC6142898.
      Citations:    
    196. Song S, Ajani JA. Reply. Gastroenterology. 2018 09; 155(3):934-935. PMID: 30098926.
      Citations:    Fields:    
    197. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295. PMID: 28628563.
      Citations: 6     Fields:    Translation:Humans
    198. Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019. PMID: 30054780.
      Citations: 2     Fields:    Translation:Humans
    199. Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, Mansfield P, Ajani J, Badgwell BD. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730. PMID: 29987602.
      Citations: 10     Fields:    Translation:Humans
    200. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728. PMID: 29949666; PMCID: PMC7703861.
      Citations: 5     Fields:    Translation:Humans
    201. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67. PMID: 29878364; PMCID: PMC7703853.
      Citations: 6     Fields:    Translation:Humans
    202. Mizrak Kaya D, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA, Nogueras-Gonz?les GM. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29. PMID: 29859338.
      Citations: 5     Fields:    Translation:Humans
    203. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90. PMID: 29843157; PMCID: PMC6067962.
      Citations: 1     Fields:    Translation:Humans
    204. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017. PMID: 29748883; PMCID: PMC7703854.
      Citations: 12     Fields:    Translation:Humans
    205. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018 05; 24(5):556-562. PMID: 29736026; PMCID: PMC6076433.
      Citations: 154     Fields:    Translation:HumansAnimalsCells
    206. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013. PMID: 29730720; PMCID: PMC6515902.
      Citations: 8     Fields:    Translation:Humans
    207. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777. PMID: 29725014; PMCID: PMC5934392.
      Citations: 100     Fields:    Translation:HumansAnimalsCells
    208. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353. PMID: 29705797; PMCID: PMC6067648.
      Citations:    Fields:    Translation:Humans
    209. Moehler M, Boku N, Ajani JA, Ryu MH, Guenther S, Chand V, Bang YJ, Taieb J, Ya?ez Ruiz E. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev. 2018 May; 66:104-113. PMID: 29730461.
      Citations: 36     Fields:    Translation:Humans
    210. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333. PMID: 29679346; PMCID: PMC7703860.
      Citations: 4     Fields:    Translation:Humans
    211. Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat. 2018 Apr 04; 4. PMID: 34113719; PMCID: PMC8188734.
      Citations: 2     
    212. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325. PMID: 26908161.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    213. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med. 2018 Mar; 4(1):8-17. PMID: 29756119; PMCID: PMC5938285.
      Citations: 1     
    214. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, Ajani J, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3. PMID: 29605441.
      Citations: 3     Fields:    Translation:Humans
    215. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus. 2018 Mar 01; 31(3). PMID: 29579257.
      Citations: 4     Fields:    Translation:Humans
    216. Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 03 01; 124(5):998-1007. PMID: 29393964; PMCID: PMC5937252.
      Citations: 15     Fields:    Translation:Humans
    217. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. J Thorac Dis. 2018 Feb; 10(2):699-702. PMID: 29607137; PMCID: PMC5864622.
      Citations: 3     
    218. Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med. 2018 Feb; 6(4):78. PMID: 29666801; PMCID: PMC5890037.
      Citations: 3     
    219. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2018 Feb; 6(4):80. PMID: 29666803; PMCID: PMC5890029.
      Citations: 1     
    220. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106. PMID: 29218623; PMCID: PMC5826863.
      Citations: 3     Fields:    Translation:Humans
    221. Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via?Integrin Signaling. Gastroenterology. 2018 04; 154(5):1524-1537.e6. PMID: 29274868.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    222. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160. PMID: 29248170; PMCID: PMC5999560.
      Citations: 51     Fields:    Translation:HumansPHPublic Health
    223. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018 01; 7(1):123-133. PMID: 29239137; PMCID: PMC5773977.
      Citations: 67     Fields:    Translation:Humans
    224. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337. PMID: 29235564; PMCID: PMC5808035.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    225. Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol. 2018 Mar; 117(4):707-709. PMID: 29228462; PMCID: PMC7726708.
      Citations: 1     Fields:    Translation:HumansCells
    226. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018 01; 18(1):19-38. PMID: 29202614.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    227. Mizrak Kaya D, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, Ajani JA, Nogueras-Gonz?lez GM. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684. PMID: 29205363; PMCID: PMC5878692.
      Citations: 7     Fields:    Translation:Humans
    228. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol. 2017 Dec; 8(6):1009-1017. PMID: 29299361; PMCID: PMC5750173.
      Citations: 11     
    229. Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2018 02; 17(2):443-454. PMID: 29167315; PMCID: PMC5805581.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    230. Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61. PMID: 29136404; PMCID: PMC5765229.
      Citations: 8     Fields:    Translation:HumansCells
    231. Harada K, Song S, Baba H, Ajani JA. Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma. Shanghai Chest. 2017 Nov; 1. PMID: 30957072; PMCID: PMC6447035.
      Citations:    
    232. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017 10 19; 8(1):1050. PMID: 29051489; PMCID: PMC5648801.
      Citations: 57     Fields:    Translation:HumansAnimals
    233. In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9. PMID: 28948368.
      Citations: 13     Fields:    Translation:Humans
    234. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017 Nov; 24(12):3683-3691. PMID: 28895113.
      Citations: 99     Fields:    Translation:Humans
    235. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113. PMID: 28885712.
      Citations: 36     Fields:    Translation:Humans
    236. Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Elme A, Esko V, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G, DIGEST Study Group, Feliu J, Abdalla K. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 01; 28(9):2142-2148. PMID: 28911091.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    237. Bonnetain F, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, de Gramont A, Borg C, Diaz-Rubio E, Douillard JY, Larsen AK, Tournigand C. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol. 2017 Sep 01; 28(9):2077-2085. PMID: 28430862.
      Citations: 13     Fields:    Translation:Humans
    238. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570. PMID: 28819789.
      Citations: 4     Fields:    Translation:Humans
    239. Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017 08 15; 10(1):149. PMID: 28810883; PMCID: PMC5558742.
      Citations: 20     Fields:    Translation:Humans
    240. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40. PMID: 28801853.
      Citations: 37     Fields:    Translation:HumansCells
    241. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344. PMID: 28799004.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    242. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017 Aug 01; 23(15):4441-4449. PMID: 28747339; PMCID: PMC5785562.
      Citations: 136     Fields:    
    243. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655. PMID: 28728163; PMCID: PMC5572179.
      Citations: 13     Fields:    Translation:HumansCells
    244. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666. PMID: 29280460.
      Citations: 9     Fields:    Translation:Humans
    245. Ohtsu A, Muro K, Van Cutsem E, Oh SC, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS, Tabernero J, Bodoky G. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 10; 16(10):2215-2222. PMID: 28716815.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    246. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Oct 06; 8(46):81430-81440. PMID: 29113402; PMCID: PMC5655297.
      Citations: 9     Fields:    
    247. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248. PMID: 28683449.
      Citations: 4     Fields:    Translation:Humans
    248. Mizrak Kaya D, Dong X, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA, Nogueras-Gonz?lez GM. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135. PMID: 28685276.
      Citations: 3     Fields:    Translation:Humans
    249. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5671-5678. PMID: 28655793.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    250. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676. PMID: 29280461.
      Citations: 28     Fields:    Translation:Humans
    251. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512. PMID: 28643069.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    252. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83. PMID: 28643144; PMCID: PMC7703858.
      Citations: 19     Fields:    Translation:Humans
    253. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 01; 3:17036. PMID: 28569272.
      Citations: 172     Fields:    Translation:Humans
    254. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. 2017 Oct 03; 8(45):79356-79365. PMID: 29108314; PMCID: PMC5668047.
      Citations:    Fields:    
    255. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710. PMID: 28404924; PMCID: PMC5438684.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    256. Elimova E, Lin Q, Song S, Ajani JA. Current status of ramucirumab in gastroesophageal adenocarcinoma. Future Oncol. 2017 Aug; 13(18):1585-1592. PMID: 28436242.
      Citations:    Fields:    Translation:HumansCells
    257. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res. 2017; 6:501. PMID: 28491289; PMCID: PMC5399958.
      Citations: 1     Fields:    
    258. Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK, Thuss-Patience PC. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 05; 18(5):640-653. PMID: 28343975.
      Citations: 135     Fields:    Translation:HumansCTClinical Trials
    259. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687. PMID: 28332034.
      Citations: 22     Fields:    Translation:Humans
    260. Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017; 7(3):473-483. PMID: 28401005; PMCID: PMC5385637.
      Citations: 24     
    261. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017 Feb 07; 23(5):751-762. PMID: 28223720; PMCID: PMC5296192.
      Citations: 15     Fields:    Translation:Humans
    262. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017 Mar; 10(3):263-271. PMID: 28094573.
      Citations: 12     Fields:    Translation:Humans
    263. Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, Ajani JA, Wu X. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. Carcinogenesis. 2017 02 01; 38(2):162-167. PMID: 28062409.
      Citations: 9     Fields:    Translation:Humans
    264. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol. 2017 Apr; 13(10):919-934. PMID: 28067073; PMCID: PMC5348722.
      Citations: 3     Fields:    Translation:Humans
    265. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, Ajani JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60. PMID: 28189209.
      Citations: 4     Fields:    Translation:Humans
    266. Bartley AN, Washington MK, Ismaila N, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017 01; 13(1):53-57. PMID: 27907277.
      Citations: 2     Fields:    Translation:Humans
    267. Doll CM, Moughan J, Klimowicz A, Ho CK, Kornaga EN, Lees-Miller SP, Ajani JA, Crane CH, Kachnic LA, Okawara GS, Berk LB, Roof KS, Becker MJ, Grisell DL, Ellis RJ, Sperduto PW, Marsa GW, Guha C, Magliocco AM. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):554-562. PMID: 28126304; PMCID: PMC5687248.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    268. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb; 35(4):446-464. PMID: 28129524.
      Citations: 90     Fields:    Translation:Humans
    269. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016 Dec; 146(6):647-669. PMID: 28077399; PMCID: PMC6272805.
      Citations: 21     Fields:    Translation:Humans
    270. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363. PMID: 27841667.
      Citations: 27     Fields:    Translation:Humans
    271. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. 2016 Nov; 13(11):1041-1053. PMID: 27718753.
      Citations: 3     Fields:    
    272. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 02; 35(4):475-477. PMID: 28129519.
      Citations: 11     Fields:    Translation:Humans
    273. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382. PMID: 27794500.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    274. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965. PMID: 27778127.
      Citations: 15     Fields:    Translation:Humans
    275. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301. PMID: 27770339.
      Citations: 6     Fields:    Translation:Humans
    276. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol. 2016 12; 17(12):1628-1629. PMID: 27776842.
      Citations: 5     Fields:    Translation:Humans
    277. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-?-Catenin Signaling in Colorectal Cancer. EBioMedicine. 2016 Nov; 13:113-124. PMID: 27789274; PMCID: PMC5264449.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    278. Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374. PMID: 27729298; PMCID: PMC5263046.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    279. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer. 2017 Mar; 20(Suppl 1):92-101. PMID: 27718136.
      Citations: 17     Fields:    Translation:Humans
    280. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 10; 14(10):1286-1312. PMID: 27697982.
      Citations: 340     Fields:    Translation:Humans
    281. Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, Lee JS, Song S, Johnson RL. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology. 2016 11; 64(5):1757-1772. PMID: 27531557; PMCID: PMC5863546.
      Citations: 44     Fields:    Translation:AnimalsCells
    282. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma? Expert Opin Pharmacother. 2016 12; 17(18):2371-2374. PMID: 27652930.
      Citations: 1     Fields:    
    283. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6228-6235. PMID: 27654712; PMCID: PMC5458637.
      Citations: 14     Fields:    Translation:Humans
    284. Fuchs CS, Chau I, Melichar B, Safran H, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA, Tabernero J, Tom?ek J, Tehfe MA, Emig M. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982. PMID: 27623234; PMCID: PMC5061911.
      Citations: 32     Fields:    Translation:Humans
    285. Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc. 2016 09; 91(9):1307-18. PMID: 27594190; PMCID: PMC5712474.
      Citations:    Fields:    Translation:Humans
    286. Elimova E, Song S, Shimodaira Y, Lin Q, Ajani JA. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol. 2016 11; 23(12):3786-3791. PMID: 27503493.
      Citations:    Fields:    Translation:Humans
    287. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016 Aug; 7(4):499-505. PMID: 27563438; PMCID: PMC4963369.
      Citations: 6     
    288. Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, Ajani JA. Evolution of gastric surgery techniques and outcomes. Chin J Cancer. 2016 07 26; 35(1):69. PMID: 27460019; PMCID: PMC4962398.
      Citations: 7     Fields:    Translation:Humans
    289. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606. PMID: 27439746.
      Citations: 4     Fields:    Translation:Humans
    290. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337. PMID: 27384751.
      Citations: 27     Fields:    Translation:Humans
    291. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60. PMID: 27120436; PMCID: PMC4949128.
      Citations: 2     Fields:    Translation:Humans
    292. Charalampakis N, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA, Nogueras Gonz?lez GM. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47. PMID: 27046280; PMCID: PMC4870109.
      Citations: 16     Fields:    Translation:Humans
    293. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55. PMID: 26868957.
      Citations: 5     Fields:    Translation:Humans
    294. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9. PMID: 26850487.
      Citations: 4     Fields:    Translation:Humans
    295. Shimodaira Y, Harada K, Lin Q, Ajani JA. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Ann Transl Med. 2016 Jan; 4(2):38. PMID: 26889491; PMCID: PMC4731594.
      Citations:    
    296. Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2016; 35:104-11. PMID: 27249691.
      Citations: 8     Fields:    Translation:Humans
    297. Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1. PMID: 26680311.
      Citations: 5     Fields:    Translation:Humans
    298. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92. PMID: 26560689.
      Citations: 6     Fields:    Translation:Humans
    299. Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35. PMID: 26603684.
      Citations: 15     Fields:    Translation:Humans
    300. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32. PMID: 26564243.
      Citations: 3     Fields:    Translation:Humans
    301. Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology. 2016; 90(1):10-20. PMID: 26492090.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    302. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7. PMID: 26482869; PMCID: PMC5152567.
      Citations: 11     Fields:    Translation:Humans
    303. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10. PMID: 26393501; PMCID: PMC4659715.
      Citations: 1     Fields:    Translation:Humans
    304. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22; 6(28):25883-96. PMID: 26317542; PMCID: PMC4694873.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    305. Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol. 2015 Oct 01; 33(28):3085-91. PMID: 26324361.
      Citations: 7     Fields:    Translation:Humans
    306. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501; PMCID: PMC4663130.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    307. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K, Pech O. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606. PMID: 26296479; PMCID: PMC4820399.
      Citations: 24     Fields:    Translation:Humans
    308. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20. PMID: 26159599; PMCID: PMC4580507.
      Citations: 2     Fields:    Translation:Humans
    309. Elimova E, Ajani JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol. 2015 Jul 20; 33(21):2410. PMID: 26077236.
      Citations: 4     Fields:    Translation:Humans
    310. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62. PMID: 26059652.
      Citations: 12     Fields:    Translation:Humans
    311. Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Van Laethem JL, Cascinu S, Ajani JA, Bodoky G, Prausov? J. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17. PMID: 25707610.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    312. Shimodaira Y, Elimova E, Wadhwa R, Shiozaki H, Charalampakis N, Planjery V, Rogers JE, Song S, Ajani JA. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs. 2015; 3(6):737-746. PMID: 27570714; PMCID: PMC5001688.
      Citations:    
    313. Sanchez-Espiridion B, Liang D, Ajani JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9. PMID: 25998788; PMCID: PMC4596233.
      Citations: 17     Fields:    Translation:Humans
    314. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90. PMID: 26002780.
      Citations: 12     Fields:    Translation:Humans
    315. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81. PMID: 25872485.
      Citations: 16     Fields:    Translation:Humans
    316. Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, Ajani JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother. 2015 May; 16(7):955-60. PMID: 25850442; PMCID: PMC4743879.
      Citations: 2     Fields:    Translation:Humans
    317. Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29. PMID: 26052595.
      Citations: 16     Fields:    Translation:HumansCells
    318. Neishaboori N, Wadhwa R, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA, Nogueras-Gonz?lez GM. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9. PMID: 25765719; PMCID: PMC4498973.
      Citations: 1     Fields:    Translation:Humans
    319. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90. PMID: 25739674; PMCID: PMC4452384.
      Citations: 106     Fields:    Translation:HumansAnimalsCells
    320. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6. PMID: 25765098; PMCID: PMC4449796.
      Citations:    Fields:    Translation:Humans
    321. Ajani JA, Song S, Hochster HS, Steinberg IB. Introduction. Semin Oncol. 2015 Apr; 42 Suppl 1:S1-2. PMID: 25839663.
      Citations:    Fields:    Translation:HumansCells
    322. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52. PMID: 25642337; PMCID: PMC4294819.
      Citations: 13     
    323. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H, National comprehensive cancer network. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
      Citations: 142     Fields:    Translation:Humans
    324. Ajani JA, Hochster HS, Steinberg IB, Song S. Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17. PMID: 25839664.
      Citations: 127     Fields:    Translation:HumansCells
    325. Ajani JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how? J Natl Compr Canc Netw. 2015 Jan; 13(1):2-3. PMID: 25583763.
      Citations:    Fields:    Translation:Humans
    326. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015 Nov; 64(11):1721-31. PMID: 25385008; PMCID: PMC4680172.
      Citations: 89     Fields:    Translation:HumansCells
    327. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47. PMID: 25320502; PMCID: PMC4194548.
      Citations: 16     Fields:    Translation:Humans
    328. Wilke H, Muro K, Van Cutsem E, Oh SC, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group, Bodoky G, Rougier P. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1224-35. PMID: 25240821.
      Citations: 846     Fields:    Translation:HumansCTClinical Trials
    329. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5. PMID: 25225435; PMCID: PMC4195852.
      Citations: 27     Fields:    Translation:Humans
    330. Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41. PMID: 25091571; PMCID: PMC4239178.
      Citations: 30     Fields:    Translation:Humans
    331. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44. PMID: 25099446.
      Citations: 6     Fields:    Translation:Humans
    332. Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL, Cuellar SL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
      Citations: 15     Fields:    Translation:Humans
    333. Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57. PMID: 25003289; PMCID: PMC4100249.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    334. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71. PMID: 25038008.
      Citations: 19     Fields:    Translation:Humans
    335. Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, Ajani JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8. PMID: 24990617.
      Citations: 9     Fields:    Translation:HumansCells
    336. Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. Cancer. 2014 Oct 01; 120(19):3040-8. PMID: 24962126.
      Citations: 17     Fields:    Translation:HumansCells
    337. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9. PMID: 24925190; PMCID: PMC4105702.
      Citations: 10     Fields:    Translation:Humans
    338. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014 Aug 01; 74(15):4170-82. PMID: 24906622; PMCID: PMC4136429.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    339. Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 01; 32(19):2112-3. PMID: 24868018.
      Citations:    Fields:    Translation:Humans
    340. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014 Aug; 45(2):567-74. PMID: 24859412; PMCID: PMC4091970.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    341. Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol. 2014 Sep; 21(9):2815-6. PMID: 24756809.
      Citations:    Fields:    Translation:Humans
    342. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2015 Sep; 54(9):880-8. PMID: 24756984.
      Citations: 14     Fields:    Translation:HumansCells
    343. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823; PMCID: PMC4039117.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    344. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79. PMID: 24605771.
      Citations: 5     Fields:    Translation:Humans
    345. Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, Muddasani R, Lu V, Tan D, Ajani JA, Wei Q. Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2015 Jun; 54(6):449-58. PMID: 24302553.
      Citations: 10     Fields:    Translation:Humans
    346. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14. PMID: 24197760.
      Citations: 18     Fields:    Translation:Humans
    347. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8. PMID: 24199704.
      Citations: 8     Fields:    Translation:Humans
    348. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
      Citations: 55     Fields:    Translation:HumansCells
    349. Dhupar R, Correa AM, Ajani J, Betancourt S, Mehran RJ, Swisher SG, Hofstetter WL. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6. PMID: 24152134.
      Citations: 3     Fields:    Translation:Humans
    350. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10. PMID: 24145339; PMCID: PMC3837091.
      Citations: 20     Fields:    Translation:Humans
    351. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55. PMID: 24061039; PMCID: PMC3927982.
      Citations: 195     Fields:    Translation:HumansAnimals
    352. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7. PMID: 24051869.
      Citations: 13     Fields:    Translation:Humans
    353. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 01; 31(31):3935-43. PMID: 24043745; PMCID: PMC5950503.
      Citations: 201     Fields:    Translation:HumansCTClinical Trials
    354. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45. PMID: 24035327; PMCID: PMC3938865.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    355. Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013; 8(9):e71994. PMID: 24023723; PMCID: PMC3759385.
      Citations: 17     Fields:    Translation:Humans
    356. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9. PMID: 23994746.
      Citations: 5     Fields:    Translation:Humans
    357. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6. PMID: 23996928; PMCID: PMC3845893.
      Citations: 21     Fields:    Translation:HumansCells
    358. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663; PMCID: PMC3937600.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    359. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91. PMID: 23845841; PMCID: PMC3786201.
      Citations: 43     Fields:    Translation:Humans
    360. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using ?-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1797-804. PMID: 23904462; PMCID: PMC3824382.
      Citations: 7     Fields:    Translation:HumansCells
    361. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24. PMID: 23899532.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    362. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9. PMID: 23860252.
      Citations: 17     Fields:    Translation:Humans
    363. Ajani JA. Challenges imposed by the complexity of cancer genome. Lancet Oncol. 2013 Jul; 14(8):e291-2. PMID: 23816294.
      Citations:    Fields:    Translation:Humans
    364. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 2013 Nov; 34(11):2521-4. PMID: 23803692; PMCID: PMC3810839.
      Citations: 19     Fields:    Translation:HumansCells
    365. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95. PMID: 23718298.
      Citations: 12     Fields:    Translation:Humans
    366. Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69. PMID: 23715646; PMCID: PMC4998180.
      Citations: 10     Fields:    Translation:Humans
    367. Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, Ajani JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013; 8(5):e64973. PMID: 23724109; PMCID: PMC3665554.
      Citations: 17     Fields:    Translation:HumansCells
    368. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H, National Comprehensive Cancer Network. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46. PMID: 23667204.
      Citations: 211     Fields:    Translation:Humans
    369. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168; PMCID: PMC3740061.
      Citations: 6     Fields:    Translation:Humans
    370. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51. PMID: 23355076.
      Citations: 3     Fields:    Translation:Humans
    371. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-? adaptor ?2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 01; 73(7):2159-69. PMID: 23536563; PMCID: PMC3745222.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    372. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205. PMID: 23466817; PMCID: PMC3608471.
      Citations: 53     Fields:    Translation:HumansCells
    373. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69. PMID: 23639645.
      Citations: 27     Fields:    Translation:HumansCells
    374. Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15. PMID: 23350713.
      Citations: 1     Fields:    Translation:Humans
    375. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70. PMID: 23303654.
      Citations: 14     Fields:    Translation:Humans
    376. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):60-6. PMID: 23307982.
      Citations: 54     Fields:    Translation:Humans
    377. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6. PMID: 23247658; PMCID: PMC3629896.
      Citations: 41     Fields:    Translation:Humans
    378. Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2. PMID: 23221793.
      Citations:    Fields:    Translation:Humans
    379. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013 Feb; 10(2):109-18. PMID: 23165235; PMCID: PMC3855852.
      Citations: 48     Fields:    Translation:HumansAnimals
    380. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51. PMID: 23150707; PMCID: PMC3515768.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    381. Das P, Strong VE, Ajani JA. Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options. Gastrointest Cancer Res. 2012 Nov; 5(6):203-4. PMID: 23293702; PMCID: PMC3533849.
      Citations: 1     
    382. Swisher S, Ajani J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet. 2012 Sep 08; 380(9845):883; author reply 885-6. PMID: 22959377.
      Citations: 2     Fields:    Translation:Humans
    383. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9. PMID: 22950385.
      Citations: 41     Fields:    Translation:Humans
    384. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4. PMID: 22964903; PMCID: PMC3832345.
      Citations: 12     Fields:    Translation:Humans
    385. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol. 2012 Oct; 5(5):355-60. PMID: 26181075.
      Citations: 2     Fields:    
    386. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
      Citations: 21     Fields:    Translation:Humans
    387. Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F, First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel, Lutz MP, H?lscher A. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov; 48(16):2941-53. PMID: 22921186.
      Citations: 59     Fields:    Translation:Humans
    388. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85. PMID: 22867894; PMCID: PMC3923623.
      Citations: 100     Fields:    Translation:Humans
    389. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404. PMID: 22853875; PMCID: PMC3869451.
      Citations: 6     Fields:    Translation:Humans
    390. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4. PMID: 22825372.
      Citations:    Fields:    Translation:Humans
    391. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642. PMID: 22831985; PMCID: PMC3457750.
      Citations: 27     Fields:    Translation:Humans
    392. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012 Jul; 24(4):448-53. PMID: 22581355.
      Citations:    Fields:    Translation:Humans
    393. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11. PMID: 22735568.
      Citations: 72     Fields:    Translation:HumansCells
    394. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51. PMID: 22677933.
      Citations: 3     Fields:    Translation:Humans
    395. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 01; 30(19):2327-33. PMID: 22585691; PMCID: PMC4517071.
      Citations: 305     Fields:    Translation:HumansCTClinical Trials
    396. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87. PMID: 22439934; PMCID: PMC3350095.
      Citations: 197     Fields:    Translation:HumansAnimalsCells
    397. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9. PMID: 22436793; PMCID: PMC3795392.
      Citations: 10     Fields:    Translation:Humans
    398. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9. PMID: 22488092.
      Citations: 2     Fields:    Translation:Humans
    399. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51. PMID: 22417808; PMCID: PMC3923631.
      Citations: 40     Fields:    Translation:HumansPHPublic Health
    400. Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5. PMID: 22392288.
      Citations: 1     Fields:    Translation:Humans
    401. Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res. 2012 Mar; 5(2):49-57. PMID: 22690258; PMCID: PMC3369601.
      Citations: 6     
    402. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20. PMID: 22331947.
      Citations: 3     Fields:    Translation:Humans
    403. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13. PMID: 22328056.
      Citations: 14     Fields:    Translation:Humans
    404. Ajani JA, Swisher SG. Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 2012 Jan; 19(1):3-4. PMID: 21989665.
      Citations: 4     Fields:    Translation:Humans
    405. Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012 Sep 01; 118(17):4346-53. PMID: 22213102; PMCID: PMC3831524.
      Citations: 14     Fields:    Translation:Humans
    406. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20. PMID: 22172216.
      Citations: 9     Fields:    Translation:Humans
    407. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22. PMID: 22150920.
      Citations: 8     Fields:    Translation:Humans
    408. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):581-6. PMID: 22137021.
      Citations: 17     Fields:    Translation:Humans
    409. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012 Feb; 75(2):242-53. PMID: 22115605.
      Citations: 61     Fields:    Translation:Humans
    410. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62. PMID: 21992792; PMCID: PMC3237863.
      Citations: 128     Fields:    Translation:HumansAnimalsCells
    411. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40. PMID: 22565611; PMCID: PMC3747650.
      Citations: 87     Fields:    Translation:Humans
    412. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3. PMID: 21962263; PMCID: PMC4041623.
      Citations: 26     Fields:    Translation:Humans
    413. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500. PMID: 21985847.
      Citations:    Fields:    Translation:Humans
    414. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. PMID: 22211134; PMCID: PMC3170070.
      Citations:    Fields:    
    415. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87. PMID: 21900218.
      Citations: 84     Fields:    Translation:Humans
    416. Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):811-3. PMID: 21900215.
      Citations:    Fields:    Translation:Humans
    417. Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11. PMID: 21900220.
      Citations: 3     Fields:    Translation:Humans
    418. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
      Citations: 63     Fields:    Translation:Humans
    419. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53. PMID: 21602659.
      Citations: 11     Fields:    Translation:Humans
    420. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67. PMID: 21365188; PMCID: PMC4086148.
      Citations: 1     Fields:    Translation:Humans
    421. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26. PMID: 21675835.
      Citations: 10     Fields:    Translation:Humans
    422. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3. PMID: 21606421.
      Citations:    Fields:    Translation:Humans
    423. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2011 May; 4(3):96-105. PMID: 22043325; PMCID: PMC3201643.
      Citations: 3     
    424. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11. PMID: 21684283; PMCID: PMC3152688.
      Citations: 165     Fields:    Translation:Humans
    425. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72. PMID: 21507583; PMCID: PMC3796353.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    426. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1336-42. PMID: 21470796; PMCID: PMC4086056.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    427. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33. PMID: 21456015; PMCID: PMC3144261.
      Citations: 28     Fields:    Translation:Humans
    428. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 01; 17(7):1850-7. PMID: 21447720; PMCID: PMC3078023.
      Citations: 167     Fields:    Translation:Humans
    429. Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res. 2011 Mar; 4(2):39. PMID: 21673873; PMCID: PMC3109889.
      Citations:    
    430. Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39. PMID: 21226634.
      Citations: 9     Fields:    Translation:Humans
    431. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011 Jan 01; 128(1):132-43. PMID: 20309880; PMCID: PMC2937084.
      Citations: 77     Fields:    Translation:HumansCells
    432. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74. PMID: 21123005; PMCID: PMC4028959.
      Citations: 46     Fields:    Translation:HumansPHPublic Health
    433. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30; 5(11):e15074. PMID: 21152079; PMCID: PMC2994829.
      Citations: 77     Fields:    Translation:Humans
    434. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27. PMID: 21136578.
      Citations: 20     Fields:    Translation:Humans
    435. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010 Nov; 26(6):640-6. PMID: 20827183.
      Citations: 20     Fields:    Translation:Humans
    436. Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak. 2010 Oct 26; 10:65. PMID: 20977768; PMCID: PMC2987967.
      Citations: 2     Fields:    Translation:Humans
    437. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30. PMID: 20960497; PMCID: PMC3080168.
      Citations: 17     Fields:    Translation:Humans
    438. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6. PMID: 20956625; PMCID: PMC3018356.
      Citations: 51     Fields:    Translation:Humans
    439. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94. PMID: 20629031.
      Citations: 6     Fields:    Translation:Humans
    440. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9. PMID: 20732514.
      Citations: 23     Fields:    Translation:Humans
    441. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13. PMID: 20564111; PMCID: PMC3831519.
      Citations: 39     Fields:    Translation:Humans
    442. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      Citations: 12     Fields:    Translation:Humans
    443. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG, M. D. Anderson Esophageal Cancer Group, University of Rochester School of Medicine and Dentistry Foregut Group. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9. PMID: 20803613.
      Citations: 22     Fields:    Translation:Humans
    444. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
      Citations: 10     Fields:    Translation:Humans
    445. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41. PMID: 20701442.
      Citations: 7     Fields:    Translation:Humans
    446. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86. PMID: 20651033; PMCID: PMC3932797.
      Citations: 45     Fields:    Translation:Humans
    447. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 01; 116(11):2511-8. PMID: 20301114.
      Citations: 26     Fields:    Translation:Humans
    448. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA. 2010 May 05; 303(17):1753-4. PMID: 20442394.
      Citations: 61     Fields:    Translation:Humans
    449. Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1. PMID: 20502055.
      Citations: 1     Fields:    Translation:Humans
    450. Ajani JA. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol. 2010 May 20; 28(15):e243-4; author reply e245. PMID: 20368554.
      Citations: 2     Fields:    Translation:Humans
    451. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25. PMID: 20410334.
      Citations:    Fields:    Translation:Humans
    452. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63. PMID: 20143431.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    453. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):378-409. PMID: 20410333.
      Citations: 60     Fields:    Translation:Humans
    454. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56. PMID: 20339140; PMCID: PMC2857801.
      Citations: 16     Fields:    Translation:Humans
    455. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
      Citations: 18     Fields:    Translation:Humans
    456. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53. PMID: 20159816.
      Citations: 226     Fields:    Translation:HumansCTClinical Trials
    457. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan; 8(1):135-44. PMID: 20064295.
      Citations: 2     Fields:    Translation:Humans
    458. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
      Citations: 24     Fields:    Translation:Humans
    459. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009 Oct 16; 9:77. PMID: 19835575; PMCID: PMC2771032.
      Citations: 15     Fields:    Translation:HumansCells
    460. Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8. PMID: 19562780.
      Citations: 3     Fields:    Translation:Humans
    461. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5744-52. PMID: 19737949; PMCID: PMC2745487.
      Citations: 68     Fields:    Translation:Humans
    462. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21. PMID: 19734842.
      Citations: 2     Fields:    Translation:HumansCells
    463. Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S58-61. PMID: 20011567; PMCID: PMC2791384.
      Citations: 1     
    464. Ajani JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S79. PMID: 20011571; PMCID: PMC2791378.
      Citations:    
    465. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009 Aug 15; 115(16):3609-17. PMID: 19526592.
      Citations: 24     Fields:    Translation:HumansCells
    466. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8. PMID: 19458557.
      Citations: 1     Fields:    Translation:Humans
    467. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC, NCCN Neuroendocrine Tumors Panel Members. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47. PMID: 19635226.
      Citations: 58     Fields:    Translation:Humans
    468. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
      Citations:    Fields:    Translation:Humans
    469. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res. 2009 Jun 30; 28:94. PMID: 19566948; PMCID: PMC2717936.
      Citations: 12     Fields:    Translation:Humans
    470. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):816-23. PMID: 19525073; PMCID: PMC3696888.
      Citations: 15     Fields:    Translation:Humans
    471. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal. 2009 May; 11(5):1083-95. PMID: 19187006; PMCID: PMC2842128.
      Citations: 14     Fields:    Translation:HumansCells
    472. Lagaly R, Horak A, Lee JH, Mansfield PF, Ajani JA. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res. 2009 May; 3(3):115-7. PMID: 19626154; PMCID: PMC2713136.
      Citations: 3     
    473. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila). 2009 May; 2(5):459-65. PMID: 19401529; PMCID: PMC2701666.
      Citations: 37     Fields:    Translation:HumansCells
    474. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105. PMID: 19399614.
      Citations: 20     Fields:    Translation:Humans
    475. Ajani JA. Chemotherapy and radiation resistance: version 2.0. J Clin Oncol. 2009 Jun 01; 27(16):2735-6; author reply 2737-8. PMID: 19398570.
      Citations:    Fields:    Translation:HumansCells
    476. Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6. PMID: 19660349.
      Citations: 21     Fields:    Translation:Humans
    477. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85. PMID: 19156915.
      Citations: 10     Fields:    Translation:HumansCells
    478. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9. PMID: 19289262.
      Citations: 22     Fields:    Translation:Humans
    479. Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Ajani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis. 2009 May; 30(5):785-92. PMID: 19270000; PMCID: PMC2675653.
      Citations: 44     Fields:    Translation:HumansCells
    480. Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol. 2009 Mar; 5(2):157-61. PMID: 19284374.
      Citations:    Fields:    
    481. Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am. 2009 Mar; 38(1):183-8, x. PMID: 19327575.
      Citations:    Fields:    Translation:Humans
    482. Baker J, Ajani J, Winther D, Martin M, Aapro MS, von Minckwitz G, Scott? F. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009 Feb; 13(1):49-59. PMID: 19201649.
      Citations: 61     Fields:    Translation:Humans
    483. Swisher SG, Zieker D, Stein H, Kitagawa Y, Law S, Ajani JA, Br?cher BL, K?nigsrainer A, Hartmann J. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009 Apr; 16(4):878-86. PMID: 19194759.
      Citations: 11     Fields:    Translation:Humans
    484. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30. PMID: 19130466.
      Citations: 19     Fields:    Translation:Humans
    485. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16. PMID: 19117343.
      Citations: 26     Fields:    Translation:Humans
    486. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009 Feb 20; 27(6):857-71. PMID: 19164214; PMCID: PMC2738430.
      Citations: 80     Fields:    Translation:HumansCells
    487. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21. PMID: 19139424; PMCID: PMC2667813.
      Citations: 12     Fields:    Translation:Humans
    488. Ajani JA. Preoperative therapy for potentially resectable localized gastric cancer. Gastrointest Cancer Res. 2009 Jan; 3(1):36-7. PMID: 19343137; PMCID: PMC2661124.
      Citations:    
    489. Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009; 69(18):2533-40. PMID: 19943706.
      Citations: 3     Fields:    Translation:HumansCells
    490. Yin M, Hu Z, Tan D, Ajani JA, Wei Q. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res. 2009 Jan 01; 1(1):44-54. PMID: 19966937; PMCID: PMC2776284.
      Citations: 21     
    491. Ajani JA, Izzo JG, Lee JS. Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol. 2009 Jan 01; 27(1):162-3; author reply 163. PMID: 19047300.
      Citations: 1     Fields:    Translation:Humans
    492. Cen P, Correa AM, Lee JH, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41. PMID: 19021684.
      Citations: 2     Fields:    Translation:Humans
    493. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32. PMID: 19021681.
      Citations: 6     Fields:    Translation:Humans
    494. Tetzlaff ED, Cheng JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008 Nov; 2(6):267-72. PMID: 19259275; PMCID: PMC2632566.
      Citations: 6     
    495. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 2008 Nov; 1(6):460-9. PMID: 19138993; PMCID: PMC2768267.
      Citations: 114     Fields:    Translation:Humans
    496. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45. PMID: 18759326.
      Citations: 37     Fields:    Translation:Humans
    497. Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct; 4(5):999-1007. PMID: 19209281; PMCID: PMC2621422.
      Citations: 9     
    498. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Esophageal Cancer Panel. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6(9):818-49. PMID: 18926093.
      Citations: 9     Fields:    Translation:Humans
    499. Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw. 2008 Oct; 6(9):813-4. PMID: 18998257.
      Citations: 15     Fields:    Translation:Humans
    500. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8. PMID: 18623381.
      Citations: 6     Fields:    Translation:Humans
    501. Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008 Oct 07; 99(7):1195; author reply 1196. PMID: 18766183; PMCID: PMC2567093.
      Citations:    Fields:    Translation:Humans
    502. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11. PMID: 18670347.
      Citations: 41     Fields:    Translation:Humans
    503. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008 Sep 01; 113(5):945-55. PMID: 18623382.
      Citations: 24     Fields:    Translation:Humans
    504. Ajani JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? Nat Clin Pract Oncol. 2008 Sep; 5(9):508-9. PMID: 18628737.
      Citations: 1     Fields:    
    505. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 01; 26(28):4551-6. PMID: 18574157; PMCID: PMC2653130.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    506. Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008 Jul; 31(7):360-1. PMID: 18596381.
      Citations: 1     Fields:    Translation:Humans
    507. Ajani JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):414-5. PMID: 18560397.
      Citations:    Fields:    
    508. Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun; 8(6):975-91. PMID: 18533807.
      Citations: 6     Fields:    Translation:Humans
    509. Baker J, Ajani J, Winther D, Martin M, Aapro MS, von Minckwitz G, Scott? F. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008 Jul; 12(3):253-68. PMID: 18501674.
      Citations: 11     Fields:    Translation:Humans
    510. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008; 21(7):575-81. PMID: 18459989.
      Citations: 11     Fields:    Translation:Humans
    511. Ajani JA, Schmoll HJ. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2008 May; 2(3 Suppl):S47-50. PMID: 19352469; PMCID: PMC2664914.
      Citations:    
    512. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):167-72. PMID: 18406886.
      Citations: 4     Fields:    Translation:Humans
    513. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21. PMID: 18430910.
      Citations: 240     Fields:    Translation:HumansCTClinical Trials
    514. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 2008 Apr 15; 68(8):2632-40. PMID: 18413730; PMCID: PMC2377413.
      Citations: 29     Fields:    Translation:Humans
    515. Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70. PMID: 18398613.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    516. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23. PMID: 18323556.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    517. Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs. 2008 Jul; 12(3):227-32. PMID: 18329956.
      Citations: 1     Fields:    Translation:Humans
    518. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7. PMID: 18205187.
      Citations: 21     Fields:    Translation:Humans
    519. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol. 2008 Mar; 3(3):277-82. PMID: 18317071.
      Citations: 17     Fields:    Translation:Humans
    520. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar; 13(1):135-44. PMID: 18321153.
      Citations: 3     Fields:    Translation:HumansAnimals
    521. Cen P, Tetzlaff ED, Ajani JA. Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results. Ther Clin Risk Manag. 2008 Feb; 4(1):137-40. PMID: 18728703; PMCID: PMC2503649.
      Citations:    
    522. Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 01; 112(3):503-10. PMID: 18072264.
      Citations: 3     Fields:    Translation:Humans
    523. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008 Jan; 2(1):10-4. PMID: 19259318; PMCID: PMC2630809.
      Citations: 16     
    524. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7. PMID: 17899453.
      Citations: 31     Fields:    Translation:Humans
    525. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7. PMID: 18164837; PMCID: PMC4741525.
      Citations: 14     Fields:    Translation:Humans
    526. Ajani JA. The area between the curves gets no respect: is it because of the median madness? J Clin Oncol. 2007 Dec 01; 25(34):5531. PMID: 18048834.
      Citations: 1     Fields:    Translation:Humans
    527. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90. PMID: 17896785.
      Citations: 10     Fields:    Translation:Humans
    528. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25. PMID: 18059229.
      Citations: 14     Fields:    Translation:Humans
    529. Izzo JG, Ajani JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol. 2007 Nov 01; 25(31):4865-7. PMID: 17971580.
      Citations: 4     Fields:    Translation:Humans
    530. Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S13-6. PMID: 19330058; PMCID: PMC2659796.
      Citations:    
    531. Kachnic LA, Ajani JA, Philip PA. Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S4-7. PMID: 19330059; PMCID: PMC2659792.
      Citations: 1     
    532. Hochster HS, O'Reilly EM, Ajani JA, Venook AP. Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S8-S12. PMID: 19330060; PMCID: PMC2659794.
      Citations: 1     
    533. Cen P, Ajani JA. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol. 2007 Nov; 23(6):631-5. PMID: 17906439.
      Citations: 1     Fields:    Translation:Humans
    534. Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol. 2007 Dec; 14(12):3290-2. PMID: 17932722; PMCID: PMC2077914.
      Citations: 1     Fields:    Translation:Humans
    535. Ajani JA, Correa AM, Swisher SG, Wu TT. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007 Sep 20; 25(27):4315-6. PMID: 17878485.
      Citations: 3     Fields:    Translation:Humans
    536. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95. PMID: 17636525.
      Citations: 6     Fields:    Translation:Humans
    537. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Radiation Therapy Oncology Group, USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24):3719-25. PMID: 17704421.
      Citations: 181     Fields:    Translation:Humans
    538. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E, V-325 Study Group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 01; 25(22):3210-6. PMID: 17664468.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    539. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5. PMID: 17643602.
      Citations: 28     Fields:    Translation:Humans
    540. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, V-325 Study Group. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 01; 25(22):3205-9. PMID: 17664467.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    541. Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol. 2007 Jul; 19(4):396-400. PMID: 17545807.
      Citations: 3     Fields:    Translation:Humans
    542. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Jul; 1(4):146-54. PMID: 19262703; PMCID: PMC2632523.
      Citations: 23     
    543. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5. PMID: 17548685.
      Citations: 9     Fields:    Translation:Humans
    544. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15; 109(10):1989-95. PMID: 17397035.
      Citations: 15     Fields:    Translation:Humans
    545. Sakata Y, Ajani JA, Fujii M, Hyodo I, Kim YH. Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointest Cancer Res. 2007 May; 1(3):107-14. PMID: 19262716; PMCID: PMC2632816.
      Citations:    
    546. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol. 2007 Apr; 34(2 Suppl 1):S2-6. PMID: 17449347.
      Citations: 9     Fields:    Translation:HumansCells
    547. Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, Liao Z, Ajani J, Stevens C, Komaki R. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1030-5. PMID: 17398033.
      Citations: 25     Fields:    Translation:Humans
    548. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800. PMID: 17379452.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    549. Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JH, Gastric Patient Care Evaluation Group from the Commission on Cancer. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg. 2007 Apr; 11(4):410-9; discussion 419-20. PMID: 17436123; PMCID: PMC1852379.
      Citations: 19     Fields:    Translation:Humans
    550. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007 Aug 16; 26(38):5674-9. PMID: 17353904.
      Citations: 111     Fields:    Translation:HumansCells
    551. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7. PMID: 17342569.
      Citations: 21     Fields:    Translation:Humans
    552. Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? J Clin Oncol. 2007 Mar 01; 25(7):906-7; author reply 908-9. PMID: 17327615.
      Citations:    Fields:    Translation:Humans
    553. Ajani JA. Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res. 2007 Mar; 1(2 Suppl):S16-21. PMID: 19343156; PMCID: PMC2661559.
      Citations: 6     
    554. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707. PMID: 17308274.
      Citations: 22     Fields:    Translation:Humans
    555. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67. PMID: 17211865.
      Citations: 92     Fields:    Translation:Humans
    556. Wang LW, Li Q, Hua ZL, Zhou F, Keping X, Daoyan W, Yao J, Ajani J. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11. PMID: 17645844.
      Citations: 3     Fields:    Translation:HumansCells
    557. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9. PMID: 17289885.
      Citations: 20     Fields:    Translation:HumansCells
    558. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40. PMID: 17133415.
      Citations: 27     Fields:    Translation:Humans
    559. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40. PMID: 17200360.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    560. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34. PMID: 17146785.
      Citations: 23     Fields:    Translation:Humans
    561. Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc. 2007 Jan; 65(1):70-6. PMID: 17185082.
      Citations: 34     Fields:    Translation:Humans
    562. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007 Jan; 31(1):58-64. PMID: 17197919.
      Citations: 43     Fields:    Translation:Humans
    563. Izzo JG, Luthra R, Sims-Mourtada J, Chao KS, Lee JH, Wu TT, Correa AM, Luthra M, Aggarwal B, Hung MC, Ajani JA. Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S3-6. PMID: 19360144; PMCID: PMC2666833.
      Citations: 5     
    564. Hu Z, Ajani JA, Wei Q. Molecular epidemiology of gastric cancer: current status and future prospects. Gastrointest Cancer Res. 2007 Jan; 1(1):12-9. PMID: 19262698; PMCID: PMC2632516.
      Citations: 13     
    565. Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5. PMID: 17178277.
      Citations: 4     Fields:    Translation:Humans
    566. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol. 2006 Dec 01; 24(34):5473-4; author reply 5474-6. PMID: 17135655.
      Citations: 5     Fields:    Translation:Humans
    567. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80. PMID: 17075877.
      Citations: 21     Fields:    Translation:Humans
    568. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Kr?ppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006 Nov 01; 12(21):6395-402. PMID: 17085651.
      Citations: 52     Fields:    Translation:HumansCells
    569. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 01; 24(31):4991-7. PMID: 17075117.
      Citations: 714     Fields:    Translation:HumansCTClinical Trials
    570. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 01; 12(21):6565-72. PMID: 17085672.
      Citations: 64     Fields:    Translation:HumansAnimals
    571. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50. PMID: 17121931.
      Citations: 21     Fields:    Translation:Humans
    572. Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res. 2006 Dec 01; 602(1-2):143-50. PMID: 17011594.
      Citations: 2     Fields:    Translation:HumansCells
    573. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 01; 107(7):1475-82. PMID: 16944539.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    574. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 01; 107(7):1467-74. PMID: 16955509.
      Citations: 8     Fields:    Translation:Humans
    575. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8. PMID: 17006988; PMCID: PMC4088233.
      Citations: 10     Fields:    Translation:Humans
    576. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74. PMID: 16874819.
      Citations: 10     Fields:    Translation:Humans
    577. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs. 2006 Sep; 24(5):441-6. PMID: 16586011.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    578. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20; 24(24):3953-8. PMID: 16921048.
      Citations: 129     Fields:    Translation:HumansCTClinical Trials
    579. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006 Aug 15; 107(4):676-85. PMID: 16847885.
      Citations: 18     Fields:    Translation:Humans
    580. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother. 2006 Aug; 7(12):1627-31. PMID: 16872265.
      Citations: 3     Fields:    Translation:Humans
    581. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2006 Aug 21; 95(4):450-6. PMID: 16880795; PMCID: PMC2360664.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    582. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604. PMID: 16899607.
      Citations: 44     Fields:    Translation:Humans
    583. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006 Aug 01; 12(15):4590-7. PMID: 16899606.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    584. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer. 2006 Jul 15; 107(2):221-31. PMID: 16770784.
      Citations: 19     Fields:    Translation:Humans
    585. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7. PMID: 16683077.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    586. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98. PMID: 16785472.
      Citations: 62     Fields:    Translation:Humans
    587. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86. PMID: 17409902.
      Citations: 15     Fields:    Translation:Humans
    588. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun; 33 Suppl 1:117-20. PMID: 16897985.
      Citations: 1     Fields:    Translation:Humans
    589. Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 01; 106(9):1908-16. PMID: 16568451.
      Citations: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    590. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47. PMID: 16569387.
      Citations: 5     Fields:    Translation:Humans
    591. Yasui W, Ajani JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci. 2006 Apr; 97(4):328-31. PMID: 16630126.
      Citations:    Fields:    Translation:HumansAnimals
    592. Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2006 Apr; 4(4):375-82. PMID: 16569390.
      Citations: 3     Fields:    Translation:Humans
    593. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66. PMID: 16569388.
      Citations: 11     Fields:    Translation:Humans
    594. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9. PMID: 17409865.
      Citations: 26     Fields:    Translation:Humans
    595. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25. PMID: 16456809.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    596. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7. PMID: 16446338.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    597. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8. PMID: 16353210.
      Citations: 20     Fields:    Translation:Humans
    598. Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S, National Comprehensive Cancer Network. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38. PMID: 16451769.
      Citations: 4     Fields:    Translation:Humans
    599. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54. PMID: 16401681.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    600. Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer. 2006; 9(2):140-3. PMID: 16767371.
      Citations:    Fields:    Translation:Humans
    601. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7. PMID: 16722991.
      Citations: 4     Fields:    Translation:Humans
    602. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005 Dec 15; 24(56):8268-76. PMID: 16170369.
      Citations: 23     Fields:    Translation:AnimalsCells
    603. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67. PMID: 16344314.
      Citations: 49     Fields:    Translation:Humans
    604. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72. PMID: 16399296.
      Citations: 1     Fields:    Translation:Humans
    605. Shao L, Lin J, Huang M, Ajani JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer. 2005 Dec; 44(4):415-22. PMID: 16114035.
      Citations: 5     Fields:    Translation:HumansCells
    606. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72. PMID: 16245310.
      Citations: 39     Fields:    Translation:Humans
    607. Ajani J, Allgood V. Molecular mechanisms in cancer: what should clinicians know? Semin Oncol. 2005 Dec; 32(6 Suppl 8):2-4. PMID: 16360003.
      Citations: 8     Fields:    Translation:Humans
    608. Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother. 2005 Dec; 6(16):2805-12. PMID: 16318431.
      Citations: 3     Fields:    Translation:HumansAnimals
    609. Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, Ajani JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S11-5. PMID: 16399423.
      Citations: 6     Fields:    Translation:Humans
    610. Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S87-9. PMID: 16399440.
      Citations: 1     Fields:    Translation:Humans
    611. Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S78-81. PMID: 16399438.
      Citations: 16     Fields:    Translation:HumansAnimals
    612. Ajani JA. Introduction. Semin Oncol. 2005 Dec; 32(6 Suppl 8):1. PMID: 16360002.
      Citations:    Fields:    Translation:Humans
    613. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8. PMID: 16242255.
      Citations: 3     Fields:    Translation:Humans
    614. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9. PMID: 16242257.
      Citations: 62     Fields:    Translation:Humans
    615. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6. PMID: 16118804.
      Citations: 29     Fields:    Translation:Humans
    616. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602. PMID: 16134179.
      Citations: 106     Fields:    Translation:Humans
    617. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55. PMID: 16130133.
      Citations: 43     Fields:    Translation:Humans
    618. Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct; 23(5):479-84. PMID: 16133799.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    619. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65. PMID: 16145066.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    620. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20; 23(24):5660-7. PMID: 16110025.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    621. Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther. 2005 Aug; 5(4):719-25. PMID: 16111471.
      Citations: 4     Fields:    Translation:Humans
    622. Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005 Aug; 140(2):325-7. PMID: 16086962.
      Citations: 16     Fields:    Translation:Humans
    623. Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005 Aug; 29(8):1079-85. PMID: 16006804.
      Citations: 55     Fields:    Translation:Humans
    624. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20. PMID: 15849517; PMCID: PMC1357136.
      Citations: 58     Fields:    Translation:Humans
    625. Agarwal B, Swisher SG, Ajani J, Kelly K, Komaki RR, Abu-Hamda E, Correa AM, Roth JA. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23. PMID: 15854962.
      Citations: 3     Fields:    Translation:Humans
    626. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103. PMID: 15860869.
      Citations: 32     Fields:    Translation:Humans
    627. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):826-9. PMID: 15824151.
      Citations: 5     Fields:    Translation:Humans
    628. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 01; 103(7):1347-55. PMID: 15719440.
      Citations: 137     Fields:    Translation:Humans
    629. Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol. 2005 Jul 01; 23(19):4256-8. PMID: 15781878.
      Citations: 5     Fields:    Translation:Humans
    630. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36. PMID: 15788671.
      Citations: 26     Fields:    Translation:Humans
    631. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64. PMID: 15708243.
      Citations: 36     Fields:    Translation:Humans
    632. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44. PMID: 15718321.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    633. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93. PMID: 15746037.
      Citations: 58     Fields:    Translation:HumansCells
    634. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol. 2005 Feb; 3(2):118-24. PMID: 16166979.
      Citations: 14     Fields:    Translation:Humans
    635. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Komaki R, Ajani JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7. PMID: 15680801.
      Citations: 13     Fields:    Translation:Humans
    636. Chak A, Canto MI, Isenberg GA, Willis JE. EUS assessment of response to chemoradiation in esophageal cancer patients. Am J Gastroenterol. 2005 Feb; 100(2):496-7; author reply 497-9. PMID: 15667512.
      Citations:    Fields:    Translation:Humans
    637. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91. PMID: 15661803.
      Citations: 25     Fields:    Translation:HumansCells
    638. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63. PMID: 15701853.
      Citations: 66     Fields:    Translation:HumansCells
    639. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28. PMID: 15747170.
      Citations: 15     Fields:    Translation:Humans
    640. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76. PMID: 16648656.
      Citations: 5     Fields:    Translation:Humans
    641. Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer. 2005; 36(1):55-8. PMID: 16227636.
      Citations: 2     Fields:    Translation:Humans
    642. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. PMID: 16368871.
      Citations: 64     Fields:    Translation:Humans
    643. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93. PMID: 15590179.
      Citations: 12     Fields:    Translation:Humans
    644. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71. PMID: 15570077.
      Citations: 168     Fields:    Translation:Humans
    645. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
      Citations: 72     Fields:    Translation:Humans
    646. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60. PMID: 15464463.
      Citations: 83     Fields:    Translation:Humans
    647. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36. PMID: 15380576.
      Citations: 16     Fields:    Translation:Humans
    648. Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10. PMID: 15300556.
      Citations: 11     Fields:    Translation:HumansCells
    649. Whiting J, Sano T, Sasako M, Ajani JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. Jpn J Clin Oncol. 2004 Aug; 34(8):481-8. PMID: 15371468.
      Citations:    Fields:    Translation:HumansAnimalsCells
    650. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 01; 101(3):518-26. PMID: 15274064.
      Citations: 182     Fields:    Translation:Humans
    651. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
      Citations: 171     Fields:    Translation:Humans
    652. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80. PMID: 15254045.
      Citations: 117     Fields:    Translation:HumansCTClinical Trials
    653. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66. PMID: 15233663.
      Citations: 7     Fields:    Translation:Humans
    654. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17. PMID: 15217947.
      Citations: 86     Fields:    Translation:HumansCells
    655. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54. PMID: 15160337.
      Citations: 19     Fields:    Translation:Humans
    656. Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep. 2004 May; 6(3):192-8. PMID: 15066230.
      Citations: 3     Fields:    Translation:Humans
    657. Ajani JA. Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol. 2004 May 01; 22(9):1763-4; author reply 1764-5. PMID: 15118003.
      Citations: 1     Fields:    Translation:Humans
    658. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol. 2004 May; 34(5):282-6. PMID: 15231865.
      Citations: 1     Fields:    Translation:Humans
    659. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96. PMID: 15067027.
      Citations: 120     Fields:    Translation:Humans
    660. Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology. 2004; 66(4):269-74. PMID: 15218293.
      Citations: 6     Fields:    Translation:Humans
    661. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004; 7(2):61-77. PMID: 15224192.
      Citations: 66     Fields:    Translation:Humans
    662. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43. PMID: 15209739.
      Citations: 13     Fields:    Translation:Humans
    663. Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev. 2004 Jan-Jun; 23(1-2):145-63. PMID: 15000155.
      Citations: 3     Fields:    Translation:Humans
    664. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64. PMID: 16035620.
      Citations: 28     Fields:    Translation:HumansAnimals
    665. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80. PMID: 14695137.
      Citations: 150     Fields:    Translation:HumansCells
    666. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22. PMID: 14630268.
      Citations: 44     Fields:    Translation:HumansPHPublic Health
    667. Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol. 2003 Dec 01; 21(23):4265-7. PMID: 14581443.
      Citations: 3     Fields:    Translation:Humans
    668. Ajani JA. It's the poison that killed him, you say! J Clin Oncol. 2003 Oct 15; 21(20):3885. PMID: 14551310.
      Citations:    Fields:    
    669. Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9. PMID: 12941201.
      Citations: 1     Fields:    Translation:Humans
    670. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7. PMID: 12909224.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    671. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2. PMID: 14569843.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    672. Ajani JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):10-2. PMID: 14569840.
      Citations:    Fields:    Translation:Humans
    673. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003 Aug; 4(8):498-505. PMID: 12901965.
      Citations: 9     Fields:    Translation:Humans
    674. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7. PMID: 12967136.
      Citations: 62     Fields:    Translation:Humans
    675. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70. PMID: 12714889.
      Citations: 20     Fields:    Translation:Humans
    676. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 01; 97(5):1195-202. PMID: 12599225.
      Citations: 20     Fields:    Translation:Humans
    677. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003; 14 Suppl 2:ii41-4. PMID: 12810457.
      Citations: 23     Fields:    Translation:Humans
    678. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan; 9(1):134-42. PMID: 12538461.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    679. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7. PMID: 14648779.
      Citations: 10     Fields:    Translation:Humans
    680. Schnirer II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol. 2003; 42(7):672-92. PMID: 14690153.
      Citations: 48     Fields:    Translation:Humans
    681. Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B, National Comprehensive Cancer Network. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):14-27. PMID: 19764147.
      Citations: 8     Fields:    Translation:Humans
    682. Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B, National Comprehensive Cancer Network. Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):28-39. PMID: 19764148.
      Citations: 9     Fields:    Translation:Humans
    683. SCOPE Steering Committee and Subcommittees. Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):317-26. PMID: 12243803.
      Citations: 1     Fields:    
    684. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5. PMID: 12192324; PMCID: PMC1422591.
      Citations: 73     Fields:    Translation:Humans
    685. Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug; 80(4):181-5. PMID: 12210031.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    686. Ajani JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused? Ann Surg Oncol. 2002 Aug; 9(7):605-6. PMID: 12167571.
      Citations:    Fields:    Translation:Humans
    687. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):89-96. PMID: 12108902.
      Citations: 10     Fields:    Translation:Humans
    688. Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002 May; 4(3):222-8. PMID: 11937012.
      Citations: 1     Fields:    Translation:Humans
    689. Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg. 2002 May; 68(5):434-40. PMID: 12013286.
      Citations: 12     Fields:    Translation:Humans
    690. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8. PMID: 12109800.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    691. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6. PMID: 11857295.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    692. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. PMID: 12491078.
      Citations: 20     Fields:    Translation:Humans
    693. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83. PMID: 11782772.
      Citations: 66     Fields:    Translation:Humans
    694. Yao JC, Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12. PMID: 12401660.
      Citations: 1     Fields:    Translation:Humans
    695. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer. 2002; 5 Suppl 1:31-4. PMID: 12772885.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    696. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001 Dec; 130(6):1078-85. PMID: 11742342.
      Citations: 76     Fields:    Translation:Humans
    697. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 06; 345(10):725-30. PMID: 11547741.
      Citations: 1159     Fields:    Translation:HumansCTClinical Trials
    698. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001 Jul 15; 92(2):279-86. PMID: 11466680.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    699. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul; 8(6):519-24. PMID: 11456051.
      Citations: 37     Fields:    Translation:Humans
    700. Tebbutt NC, Norman A, Hill M, Cunningham D. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2001 May 15; 19(10):2765-7. PMID: 11352971.
      Citations:    Fields:    Translation:Humans
    701. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4. PMID: 11301842.
      Citations: 12     Fields:    Translation:Humans
    702. Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5. PMID: 11232959.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    703. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27. PMID: 11641011.
      Citations: 1     Fields:    Translation:Humans
    704. Ajani J, Ettinger D, Kelsen DP, Hudis C, Kudelka A, Langer C, Pienta K, Safran H, Vokes EE, Yung WK, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):88-91. PMID: 11641021.
      Citations:    Fields:    Translation:Humans
    705. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3. PMID: 11561696.
      Citations: 4     Fields:    Translation:Humans
    706. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000 Dec 01; 18(23):4001-3. PMID: 11099333.
      Citations: 12     Fields:    Translation:Humans
    707. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):387-98. PMID: 12057146.
      Citations: 9     Fields:    Translation:Humans
    708. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):34-7. PMID: 11200147.
      Citations: 5     Fields:    Translation:Humans
    709. Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol. 2000 Nov; 16(6):516-21. PMID: 17031130.
      Citations: 1     Fields:    
    710. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1126-32. PMID: 10838528.
      Citations: 81     Fields:    Translation:Humans
    711. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho. 2000 May; 27 Suppl 2:392-4. PMID: 10895184.
      Citations:    Fields:    Translation:Humans
    712. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000 Mar-Apr; 6(2):78-81. PMID: 11069223.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    713. Medgyesy CD, Wolff RA, Putnam JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7. PMID: 10640955.
      Citations: 40     Fields:    Translation:Humans
    714. York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999 Dec; 6(8):771-6. PMID: 10622506.
      Citations: 47     Fields:    Translation:Humans
    715. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park). 1999 Nov; 13(11):1485-94; discussion 1497-502 passim. PMID: 10581599.
      Citations:    Fields:    Translation:Humans
    716. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999 Nov 01; 86(9):1657-68. PMID: 10547537.
      Citations: 12     Fields:    Translation:Humans
    717. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11. PMID: 10561303.
      Citations: 30     Fields:    Translation:Humans
    718. Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer. 1999 Jun 01; 85(11):2336-9. PMID: 10357402.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    719. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999 May; 51(2):153-60. PMID: 10435807.
      Citations: 25     Fields:    Translation:Humans
    720. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 Mar; 229(3):303-8. PMID: 10077040; PMCID: PMC1191693.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    721. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999 Mar-Apr; 5(2):112-4. PMID: 10198733.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    722. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999 Feb; 17(2):600-6. PMID: 10080605.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    723. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999; 17(7):474-8. PMID: 10518191.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    724. Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs. 1999; 58 Suppl 3:85-90. PMID: 10711846.
      Citations: 3     Fields:    Translation:HumansAnimals
    725. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31; 339(27):1979-84. PMID: 9869669.
      Citations: 322     Fields:    Translation:HumansCTClinical Trials
    726. NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):179-223. PMID: 10028512.
      Citations: 4     Fields:    Translation:Humans
    727. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):44-7. PMID: 9830625.
      Citations: 14     Fields:    Translation:Humans
    728. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998 Aug; 16(8):2877-85. PMID: 9704742.
      Citations: 21     Fields:    Translation:Humans
    729. Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):99-102. PMID: 9726100.
      Citations: 2     Fields:    Translation:Humans
    730. Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc. 1998 Aug; 48(2):172-9. PMID: 9717783.
      Citations: 34     Fields:    Translation:Humans
    731. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug; 4(4):269-74. PMID: 9689986.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    732. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34. PMID: 9586897.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    733. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998 Feb; 21(1):36-8. PMID: 9499254.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    734. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998 Feb; 170(2):339-44. PMID: 9456942.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    735. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs. 1998-1999; 16(4):333-5. PMID: 10426667.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    736. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998 Jan; 113(1 Suppl):112S-119S. PMID: 9438700.
      Citations: 3     Fields:    Translation:Humans
    737. Ajani JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs. 1998; 16(2):175-7. PMID: 9848582.
      Citations: 1     Fields:    Translation:Humans
    738. Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec; 20(6):573-6. PMID: 9391543.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    739. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PMID: 9427271.
      Citations:    Fields:    Translation:Humans
    740. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1996 Oct; 23(5 Suppl 12):55-8. PMID: 8941411.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    741. Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery. 1996 Jun; 119(6):611-4. PMID: 8650600.
      Citations: 35     Fields:    Translation:Humans
    742. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg. 1996 Feb; 20(2):147-56. PMID: 8661810.
      Citations: 14     Fields:    Translation:Humans
    743. Jeon HM, Lynch PM, Howard L, Ajani J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat. 1996; 7(4):327-33. PMID: 8723682.
      Citations: 2     Fields:    Translation:Humans
    744. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol. 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PMID: 7481861.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    745. Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct; 18(5):436-8. PMID: 7572763.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    746. Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9. PMID: 7607922.
      Citations: 31     Fields:    Translation:Humans
    747. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995 Jun; 22(3 Suppl 6):35-40. PMID: 7541155.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    748. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, Ajani JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):197-204. PMID: 7721616.
      Citations: 8     Fields:    Translation:Humans
    749. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20. PMID: 7754626.
      Citations: 9     Fields:    Translation:Humans
    750. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995 Jan 15; 75(2):451-6. PMID: 7812915.
      Citations: 5     Fields:    Translation:Humans
    751. Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother. 1995; 5(3):104-11. PMID: 8528966.
      Citations: 1     Fields:    Translation:Humans
    752. Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer. 1995; 31A(5):790-3. PMID: 7640055.
      Citations: 2     Fields:    Translation:Humans
    753. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer. 1995; 31A(5):665-70. PMID: 7640036.
      Citations: 2     Fields:    Translation:Humans
    754. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994 Nov; 12(11):2296-300. PMID: 7964943.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    755. Kelsen D, Ajani J, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Semin Oncol. 1994 Oct; 21(5 Suppl 8):44-8. PMID: 7524158.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    756. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann N Y Acad Sci. 1994 Sep 15; 733:479-87. PMID: 7978898.
      Citations:    Fields:    Translation:Humans
    757. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park). 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61. PMID: 7527642.
      Citations: 2     Fields:    Translation:Humans
    758. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 1994 Aug; 21(4):474-82. PMID: 8042045.
      Citations: 10     Fields:    Translation:Humans
    759. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20; 86(14):1086-91. PMID: 7912736.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    760. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994 May; 5(5):468-70. PMID: 7915537.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    761. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol. 1994 Mar; 1(2):111-6. PMID: 7834435.
      Citations: 17     Fields:    Translation:Humans
    762. Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994 Mar; 5(3):286-7. PMID: 8186177.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    763. Vassilopoulou-Sellin R, Ajani J. Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am. 1994 Mar; 23(1):53-65. PMID: 7913029.
      Citations: 3     Fields:    Translation:Humans
    764. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994 Jan 05; 86(1):51-3. PMID: 7903699.
      Citations: 7     Fields:    Translation:Humans
    765. Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest. 1994; 12(5):488-90. PMID: 7922705.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    766. Rich TA, Ajani JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol. 1994; 5 Suppl 3:9-15. PMID: 8204536.
      Citations:    Fields:    Translation:Humans
    767. Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 Suppl 3:75-80. PMID: 8204533.
      Citations: 5     Fields:    Translation:Humans
    768. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993 Dec; 114(6):1175-81; discussion 1181-2. PMID: 7903005.
      Citations: 22     Fields:    Translation:Humans
    769. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44. PMID: 8230264.
      Citations: 33     Fields:    Translation:Humans
    770. Jones DV, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer. 1993 Nov 01; 72(9):2560-3. PMID: 8402476.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    771. Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy. 1993 Nov; 25(9):587-91. PMID: 8119209.
      Citations: 2     Fields:    Translation:Humans
    772. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol. 1993 Jun; 27(3):209-15. PMID: 8210457.
      Citations: 15     Fields:    Translation:HumansAnimals
    773. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 01; 71(11):3690-6. PMID: 8490919.
      Citations: 14     Fields:    Translation:Humans
    774. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer. 1993 Feb 15; 71(4):1214-8. PMID: 8435795.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    775. Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb; 11(1):67-9. PMID: 8349439.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    776. Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer. 1993; 29A(16):2332-3. PMID: 7509166.
      Citations:    Fields:    Translation:Humans
    777. Jones DV, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest. 1993; 11(6):667-9. PMID: 8221199.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    778. Ajani JA. In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol. 1993 Jan; 11(1):193-4. PMID: 8418233.
      Citations: 2     Fields:    Translation:Humans
    779. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1993 Jan; 11(1):22-8. PMID: 8418237.
      Citations: 6     Fields:    Translation:Humans
    780. Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec; 15(6):524-7. PMID: 1449117.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    781. Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol. 1992 Dec; 19(6 Suppl 14):45-7. PMID: 1488653.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    782. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992 Oct 15; 70(8):2073-6. PMID: 1394037.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    783. Jones DV, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med. 1992 Sep; 93(3):348-9. PMID: 1524091.
      Citations:    Fields:    Translation:Humans
    784. Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug; 10(3):211-3. PMID: 1428730.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    785. Grossie VB, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol. 1992 Jul; 50(3):161-7. PMID: 1619938.
      Citations: 1     Fields:    Translation:AnimalsCells
    786. Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs. 1992 Apr; 10(1):39-42. PMID: 1376722.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    787. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992 Feb 15; 69(4):878-82. PMID: 1735078.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    788. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992; 28A(4-5):880-4. PMID: 1524915.
      Citations: 11     Fields:    Translation:Humans
    789. Grossie VB, Ota DM, Ajani JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. Invest New Drugs. 1991 Nov; 9(4):321-6. PMID: 1804805.
      Citations: 1     Fields:    Translation:Animals
    790. Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6. PMID: 1804812.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    791. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs. 1991 Nov; 9(4):369-71. PMID: 1804816.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    792. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991 Oct 01; 68(7):1501-6. PMID: 1893349.
      Citations: 30     Fields:    Translation:Humans
    793. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug; 9(3):257-9. PMID: 1783525.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    794. Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med. 1991 Aug; 115(8):807-12. PMID: 1713759.
      Citations: 1     Fields:    Translation:Humans
    795. Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. J Surg Oncol. 1991 Jun; 47(2):117-20. PMID: 2062082.
      Citations: 1     Fields:    Translation:Humans
    796. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5. PMID: 1846848.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    797. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs. 1991 Feb; 9(1):37-9. PMID: 1851142.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    798. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer. 1991 Jan 01; 67(1 Suppl):260-5. PMID: 1984825.
      Citations: 3     Fields:    Translation:Humans
    799. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec; 8(12):2027-31. PMID: 2230894.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    800. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod. 1990 Oct; 9(5):522-7. PMID: 2123922.
      Citations: 11     Fields:    Translation:Humans
    801. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul; 8(7):1231-8. PMID: 2358838.
      Citations: 17     Fields:    Translation:Humans
    802. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990 Jul; 8(7):1246-54. PMID: 2193120.
      Citations: 8     Fields:    Translation:Humans
    803. Rich TA, Hughes L, Ajani JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):710. PMID: 2318708.
      Citations:    Fields:    Translation:Humans
    804. Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990 Jan 15; 65(2):354-7. PMID: 2153046.
      Citations: 11     Fields:    Translation:Humans
    805. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21. PMID: 2149834.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    806. Nicaise C, Ajani J, Goudeau P, Rozencweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1990; 26(3):221-2. PMID: 1694112.
      Citations: 3     Fields:    Translation:Humans
    807. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. Adv Surg. 1990; 23:239-60. PMID: 2403459.
      Citations: 1     Fields:    Translation:Humans
    808. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147-59. PMID: 2400936.
      Citations: 47     Fields:    Translation:Humans
    809. Ajani JA, Ota DM, Grossie VB, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol. 1990; 26(3):223-6. PMID: 2113439.
      Citations: 3     Fields:    Translation:Humans
    810. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1153-60. PMID: 2599903.
      Citations: 17     Fields:    Translation:Humans
    811. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am. 1989 Dec; 18(4):923-30. PMID: 2559037.
      Citations:    Fields:    Translation:Humans
    812. Grossie VB, Nishioka K, Chang TH, Patenia D, Benitez MM, Ajani JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec; 13(6):590-5. PMID: 2515305.
      Citations:    Fields:    Translation:AnimalsCells
    813. Ajani JA, Ota DM, Grossie VB, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res. 1989 Oct 15; 49(20):5761-5. PMID: 2507135.
      Citations: 2     Fields:    Translation:HumansCells
    814. Ajani JA. Bolus fluorouracil for metastatic colorectal carcinoma? J Clin Oncol. 1989 Sep; 7(9):1366-7. PMID: 2769332.
      Citations:    Fields:    Translation:Humans
    815. Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol. 1989 Aug; 12(4):335-8. PMID: 2667325.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    816. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989 Aug; 87(2):221-4. PMID: 2527006.
      Citations: 29     Fields:    Translation:Humans
    817. Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. Cancer Res. 1989 Aug 01; 49(15):4159-62. PMID: 2501023.
      Citations: 2     Fields:    Translation:Animals
    818. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15; 49(14):4057-61. PMID: 2500234.
      Citations: 18     Fields:    Translation:Humans
    819. Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Ajani J, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumours. Baillieres Clin Endocrinol Metab. 1989 May; 3(1):121-52. PMID: 2679521.
      Citations: 2     Fields:    Translation:Humans
    820. Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod. 1989 Apr; 8(2):140-6. PMID: 2499663.
      Citations: 5     Fields:    Translation:Humans
    821. Tueni EA, Newman RA, Baker FL, Ajani JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. Cancer Res. 1989 Mar 01; 49(5):1099-102. PMID: 2465080.
      Citations: 2     Fields:    Translation:HumansCells
    822. Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989; 24(1):41-4. PMID: 2720890.
      Citations:    Fields:    Translation:Humans
    823. Nishioka K, Grossie VB, Ajani JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer. 1988 Nov 15; 42(5):744-7. PMID: 3141298.
      Citations:    Fields:    Translation:AnimalsCells
    824. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988 Nov; 6(11):1703-7. PMID: 3141592.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    825. Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod. 1988 Oct; 7(5):438-46. PMID: 3141591.
      Citations: 1     Fields:    Translation:Humans
    826. Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. JPEN J Parenter Enteral Nutr. 1988 Sep-Oct; 12(5):441-4. PMID: 3141639.
      Citations:    Fields:    Translation:Animals
    827. Fan D, Baker FL, Khokhar AR, Ajani JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res. 1988 Jun 01; 48(11):3135-9. PMID: 3365698.
      Citations: 2     Fields:    Translation:HumansCells
    828. Ajani JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85. PMID: 3170133.
      Citations:    Fields:    Translation:HumansCells
    829. Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr; 6(1):47-50. PMID: 2457566.
      Citations: 2     Fields:    Translation:Humans
    830. Baker FL, Ajani J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. Int J Cell Cloning. 1988 Mar; 6(2):95-105. PMID: 3373036.
      Citations:    Fields:    Translation:HumansCells
    831. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988 Mar; 108(3):340-4. PMID: 2449109.
      Citations: 22     Fields:    Translation:Humans
    832. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). Prog Clin Biol Res. 1988; 276:105-17. PMID: 3174675.
      Citations:    Fields:    Translation:HumansCells
    833. Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol. 1987 Dec; 5(12):1912-21. PMID: 3681375.
      Citations: 7     Fields:    Translation:Humans
    834. Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol. 1987 Oct; 23(10):1469-76. PMID: 2890527.
      Citations: 4     Fields:    Translation:HumansCells
    835. Grossie VB, Ota DM, Ajani JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res. 1987 Apr 01; 47(7):1836-40. PMID: 3102050.
      Citations: 5     Fields:    Translation:Animals
    836. Odaimi M, Ajani J. High-dose chemotherapy. Concepts and strategies. Am J Clin Oncol. 1987 Apr; 10(2):123-32. PMID: 3551575.
      Citations: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    837. Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1987 Apr; 10(2):139-40. PMID: 3551577.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    838. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987 Jan 15; 47(2):403-6. PMID: 3491676.
      Citations: 31     Fields:    Translation:HumansCells
    839. Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer. 1986 Oct; 54(4):607-13. PMID: 3778805; PMCID: PMC2001502.
      Citations: 2     Fields:    Translation:HumansCells
    840. Odaimi M, Ajani JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med J. 1986 Oct; 79(10):1304-6. PMID: 2429372.
      Citations: 1     Fields:    Translation:Humans
    841. Patt YZ, Boddie AW, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol. 1986 Sep; 4(9):1356-64. PMID: 2943876.
      Citations: 4     Fields:    Translation:Humans
    842. Ota DM, Grossie VB, Ajani JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer. 1986 Aug 15; 38(2):245-9. PMID: 3089944.
      Citations: 2     Fields:    Translation:AnimalsCells
    843. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986 Jul; 147(1):149-54. PMID: 2424291.
      Citations: 28     Fields:    Translation:Humans
    844. Adolphson CC, Ajani JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1986 Jun; 9(3):189-91. PMID: 3728371.
      Citations: 5     Fields:    Translation:Humans
    845. Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep. 1986 Mar; 70(3):375-9. PMID: 3955548.
      Citations: 5     Fields:    Translation:Humans
    846. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 1986 Mar; 46(3):1263-74. PMID: 3484678.
      Citations: 22     Fields:    Translation:HumansCells
    847. Ajani JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs. 1986; 4(4):383-5. PMID: 3583645.
      Citations:    Fields:    Translation:Humans
    848. Ajani JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs. 1986; 4(2):141-8. PMID: 2426218.
      Citations:    Fields:    Translation:HumansCells
    849. Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol. 1986; 111(3):273-6. PMID: 3733857.
      Citations:    Fields:    Translation:HumansCells
    850. Hortobagyi GN, Papadoupoulos NE, Frye D, Ajani J, Reuben JM. Phase I clinical study of nafazatrom. Invest New Drugs. 1986; 4(3):251-5. PMID: 3818230.
      Citations: 1     Fields:    Translation:Humans
    851. Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. JAMA. 1985 Dec 27; 254(24):3479. PMID: 2933539.
      Citations: 4     Fields:    Translation:Humans
    852. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res. 1985 Jun; 38(6):592-8. PMID: 3925242.
      Citations: 1     Fields:    Translation:AnimalsCells
    853. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28. PMID: 3998518.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    854. Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol. 1985 Feb; 8(1):69-71. PMID: 3993626.
      Citations: 2     Fields:    Translation:Humans
    855. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology. 1985; 42(2):69-71. PMID: 3921891.
      Citations: 2     Fields:    Translation:Humans
    856. Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol. 1985; 109(2):130-4. PMID: 3980561.
      Citations: 2     Fields:    Translation:HumansCells
    857. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol. 1985; 13 Suppl 16:95-100. PMID: 2580731.
      Citations: 2     Fields:    Translation:HumansCells
    858. Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep. 1984 Dec; 68(12):1507-8. PMID: 6595058.
      Citations: 2     Fields:    Translation:Humans
    859. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984 Sep; 68(9):1085-91. PMID: 6478448.
      Citations: 18     Fields:    Translation:Humans
    860. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984 Aug; 44(8):3608-12. PMID: 6744283.
      Citations: 21     Fields:    Translation:HumansCells
    861. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      Citations: 1     Fields:    Translation:Humans
    862. Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, Ajani J, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. Recent Results Cancer Res. 1984; 94:253-66. PMID: 6593776.
      Citations:    Fields:    Translation:HumansCells
    863. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer. 1983 Dec; 48(6):869-71. PMID: 6652028; PMCID: PMC2011573.
      Citations:    Fields:    Translation:Humans
    864. Legha SS, Ajani JA, Bodey GP. Phase I study of spirogermanium given daily. J Clin Oncol. 1983 May; 1(5):331-6. PMID: 6668504.
      Citations: 9     Fields:    Translation:Humans
    865. Ajani JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep. 1982 Nov; 66(11):1987-9. PMID: 6890408.
      Citations:    Fields:    Translation:Humans
    866. Ajani JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. Cancer Treat Rep. 1982 May; 66(5):1227-8. PMID: 6805950.
      Citations: 3     Fields:    Translation:Humans
    867. In reply [19]. Journal of Clinical Oncology. 23:3870-3871.
    868. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology. 23:626-632.
    869. Role of chemotherapy for advanced/recurrent gastric cancer. JAMA - Journal of the American Medical Association. 49:1565-1577.
    870. Cancer single pathways inhibitors. Gastric and Breast Cancer. 11:111-117.
    871. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine. 13:113-124.
    872. American Society of Clinical Oncology, 45th Annual Meeting - Comparison of cisplatin/S-1 tablets with cisplatin/5-FU infusions for advanced gastric cancer. P and T. 34:379-380.
    873. Erratum. Cancer. 115:2024.
    874. Seminars in Oncology. Seminars in Oncology. 32:1.
    875. How much luminal dilation (if any) is necessary prior to placement of an esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
    876. Management of a rectovesical malignant fistula with the coated wallstent. Gastrointestinal Endoscopy. 45.
    877. Erratum. Cancer. 120:3264.
    878. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials.
    879. A nomogram to predict distant metastases after multimodality therapy for patients with localized esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 14:173-179.
    880. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology.
    881. Palliation of malignant colorectal strictures with expandable metallic stents. Gastrointestinal Endoscopy. 47.
    882. Editor's commentary. Current Colorectal Cancer Reports. 1:1.
    883. Gastrointestinal malignancies in the elderly. Cancer Bulletin. 47:218-223.
    884. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
    885. Adjuvant therapy for resected gastric carcinoma. Surgical Oncology Clinics of North America. 11:431-444.
    886. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clinic Proceedings. 91:1307-1318.
    887. The biology of K-Ras and B-Raf mutations in colorectal cancer. Current Colorectal Cancer Reports. 6:206-211.
    888. Seminars in oncology. Seminars in Oncology. 29:1-2.
    889. Survival rates in T1 and T2 gastric cancer. Journal of Surgical Oncology. 114:602-606.
    890. Reply to D. Vordermark. Journal of Clinical Oncology. 27:3065.
    891. Adjuvant chemotherapy of colorectal cancer. Cancer Bulletin. 40:235-238.
    892. In Reply. JAMA - Journal of the American Medical Association. 255:3116.
    893. Barrett's esophagus. Gastrointestinal Cancer Research. 5:49-53.
    894. In reply [2]. Journal of Clinical Oncology. 25:5529-5530.
    895. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. American Journal of Dermatopathology. 21:36-38.
    896. Surgical Resection first for localized gastric adenocarcinoma. Journal of Clinical Oncology. 33:3085-3091.
    897. Corrigendum to "Docetaxel-related side effects and their management" [European Journal of Oncology Nursing 12 (2008) 253-268] (DOI. European Journal of Oncology Nursing. 12:479.
    898. Conservative management of anal and low rectal cancers with combined modality therapy. Cancer Bulletin. 41:71-74.
    899. Status of newer chemotherapeutic strategies for the treatment of metastatic gastric cancer. American Journal of Cancer. 4:65-70.
    900. Erratum. Current Opinion in Gastroenterology. 24:101.
    901. Neoadjuvant therapy for gastric cancer. Asian Journal of Surgery. 24:235-241.
    902. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology. 1-11.
    903. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology. 1-6.
    904. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy. Oncology (Switzerland). 91:55-60.
    905. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology (Switzerland).
    906. The role of docetaxel in gastric cancer. European Journal of Cancer, Supplement. 4:4-9.
    907. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.
    908. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Archives of Pathology and Laboratory Medicine. 140:1345-1363.
    909. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 14:1286-1312.
    910. Outcome of preoperative chemoradiation in localized gastric adenocarcinoma. American Journal of Hematology/ Oncology. 6:142-145.
    911. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs. 3:737-746.
    912. Development and validation of a six-gene recurrence risk score assay for gastric cancer. Clinical Cancer Research. 22:6228-6235.
    913. Introduction. Seminars in Oncology. 34.
    914. Adjuvant and neoadjuvant therapy for gastric cancer. Gastrointestinal Cancer Research. 5:203-204.
    915. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology (Switzerland).
    916. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clinical Gastroenterology and Hepatology. 13:1730-1737.
    917. The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. 143-150.
    918. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Review of Proteomics. 13:1041-1053.
    919. In reply. Journal of Clinical Oncology. 27:468-469.
    920. GCR graduates from nursery school on a fast track to editorial excellence. Gastrointestinal Cancer Research. 4:39.
    921. Introduction. Seminars in Oncology. 33:1.
    922. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Annals of Surgical Oncology.
    923. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. The Lancet Oncology. 17:1628-1629.
    924. Early clinical esophageal adenocarcinoma (cT1). European Journal of Radiology. 88:56-60.
    925. Paraneoplastic neurological syndromes associated with gastric cancer. Clinical Journal of Gastroenterology. 5:355-360.
    926. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 64:1721-1731.
    927. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Review of Gastroenterology and Hepatology. 10:383-392.
    928. Response. Gastrointestinal Endoscopy. 76:1073-1075.
    929. Gastroesophageal cancers. 3-4.
    930. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice. 9:463-471.
    931. Adhesive tumor cell culture system.
    932. Anal canal cancer. Expert Opinion on Orphan Drugs. 2:137-146.
    933. Management of advanced gastric cancer.
    934. The overall complication rate after esophageal Wallstent is related to the esophageal location of the lesion. Gastrointestinal Endoscopy. 45.
    935. Esophageal Adenocarcinoma. 67-86.
    936. Tumor factors that may affect the outcome after palliation with the esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
    937. In reply [5]. Journal of Clinical Oncology. 25:2491-2493.
    938. Therapeutic options for patients with advanced islet cell and carcinoid tumors. Regional Cancer Treatment. 3:235-242.
    939. Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma. Gastroenterology. 149:1599-1606.
    940. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 6:25883-25896.
    941. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Annals of Surgical Oncology. 1-8.
    942. Author reply [4]. Cancer. 109:1449.
    943. Operative and adjuvant treatment strategies for gastric carcinoma. Cancer Bulletin. 44:286-291.
    944. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Annals of Surgical Oncology. 1-6.
    945. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Annals of Surgical Oncology. 1-6.
    946. 1988 American Society of Clinical Oncology Meeting (ASCO 1988) - New Orleans, May 23-25, 1988. Journal of Cancer Research and Clinical Oncology. 114:533-535.
    947. Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointestinal Endoscopy. 47.
    948. Group organizational structure. International Journal of Radiation Oncology Biology Physics. 51:6-10.
    949. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer.
    950. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Annals of Translational Medicine. 4.
    951. The emerging epidemic of gastroesophageal cancers. Oncology. 21.
    952. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. Journal of Gastrointestinal Oncology. 6:45-52.
    953. The role of PI3K/PTEN/AKT/mTOR genetic variation in clinical outcomes following chemoradiotherapy for esophageal cancer. American Journal of Hematology/ Oncology. 8.
    954. Palliation of malignant dysphagia with chemoradiation therapy (ChXRT) does not increase the rate of serious complications with coated Wallstent. Gastrointestinal Endoscopy. 45.
    955. Activity of investigational agents.
    956. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer. Journal of Gastrointestinal Oncology. 7:499-505.
    957. Global chemotherapy development for gastric cancer. Gastric Cancer. 1-10.
    958. Palliation of malignant dysphagia and fistulae with the Wwallstent. Gastrointestinal Endoscopy. 45.
    959. In reply. Gastrointestinal Cancer Research. 3:218.
    960. Chemotherapy and radiotherapy for anal canal carcinoma - Reply. JAMA - Journal of the American Medical Association. 300:1411.
    961. Genome-based diagnostics and therapeutics in personalized cancer therapy. Gastric and Breast Cancer. 11:53-57.
    962. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation. Oncology (Switzerland).
    963. Seminars in Oncology. Seminars in Oncology. 32.
    964. In reply. Journal of Clinical Oncology. 26:2236-2237.
    965. Is targeted therapy possible for patients with gastric adenocarcinoma?. Expert Opinion on Pharmacotherapy. 1-4.
    966. Oxaliplatin beim kolorektal-karzinom. Onkologie. 25:1-11.
    967. Phase I study of spirogermanium (SPG) given for five consecutive days per week.
    AJANI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (1145)
    Explore
    _
    Co-Authors (248)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _